Design and synthesis of quinoline-derived thioureas as potential antihyperglycemic, anti-Alzheimer, and antioxidant agents Authors: Faiza Seraj, Maryam Maqbool, Fayaz Ali, Sridevi Chigurupati, Syeda Sumayya Tariq, Uzma Salar, Zaheer Ul-Haq, Vasudevan Mani, Shatha Ghazi Felemban, Khalid Mohammed Khan Published: 2026 ABSTRACT A library of quinoline-based thiourea hybrids 1–41 was synthesized via a single-step reaction scheme. All compounds were evaluated for their inhibitory potential against α-amylase, α-glucosidase, AChE, and BChE enzymes as well as for DPPH radical scavenging activity. Among forty-one compounds, 27–31 and 33–37 showed excellent inhibition against α-amylase (IC50 = 18.36–28.21 µM) and α-glucosidase (IC50 = 17.77–29.31 µM) compared to the standard acarbose (IC50 = 16.98 ± 0.12, 14.19 ± 0.06 µM). Moreover, compounds 27, 28, 30, 31, 34, 35, and 37 inhibited AChE (IC50 = 5.60–14.97 µM) and BChE (IC50 = 6.99–15.70 µM) with greater potency than the standard donepezil chloride (IC50 = 1.49 ± 0.13, 2.39 ± 0.06 µM). Kinetic analyses were conducted for the most active compounds to elucidate their modes of enzyme inhibition. Furthermore, molecular docking studies were conducted to explore ligand binding interactions within the enzyme active site. All synthesized derivatives were further evaluated for their DPPH radical scavenging activity, among which compounds 27, 28, 30, 31, 34, and 35 exhibited significant to moderate antioxidant potential (SC50 = 23.92–34.73 µM) compared with the reference standard ascorbic acid (SC50 = 18.28 ± 0.15 µM). Among this library, compound 31, with a difluoro group on the phenyl ring, was identified as the most potent inhibitor against all enzymes. Thus, this study suggests that the reported compounds hold the potential to be further advanced as lead anti-Alzheimer and anti-diabetic agents. Introduction Diabetes mellitus (DM) is a class of metabolic disorders that can be described by elevated blood sugar levels caused by deficiencies in the production and/or action of insulin. Chronic hyperglycemia leads to long-term harm, malfunction, and various organ dysfunction, particularly to the kidneys, eyes, heart, nerves, and blood vessels.1 It is a rapidly spreading global problem with significant health, social, and economic consequences. The International Diabetes Federation (IDF) estimates that 415 million people aged 20–79 had DM in 2015, and this number is predicted to increase by an additional 200 million by 2040.2,3 Based on disease etiology, DM is broadly classified into two major types. Type 1 DM is an autoimmune disorder characterized by immune-mediated destruction of pancreatic β-cells that produce insulin, typically starting in childhood or adolescence.6 In contrast, Type 2 DM arises from impaired insulin action and/or insulin resistance, leading to elevated blood glucose levels and hyperglycemia.4,5 It is the most prevalent type of diabetes and affects 90 to 95% of people globally. Risk rises with advancing age, obesity, poor diet, and a sedentary lifestyle.4,7,8 α-Amylase is a calcium-dependent, low-molecular-weight enzyme that facilitates digestion by hydrolyzing polysaccharides into smaller units, such as maltose and glucose.9,10 α-Glucosidase is located in the brush border of the small intestine, where it hydrolyzes starch and disaccharides into glucose, enabling their absorption.11 A viable therapeutic strategy for managing hyperglycemia involves focusing on these enzymes. Currently, acarbose, miglitol, and voglibose are the approved inhibitors. Although these inhibitors reduce glucose absorption, they may cause adverse intestinal side effects.12 Thus, studies continue to explore innovative inhibitors with greater efficacy and fewer side effects. Similarly, Alzheimer's disease (AD) is the most prevalent form of dementia, which significantly raises an individual's risk of mortality and morbidity.13 It is a progressive neurodegenerative disorder characterized by memory impairment and cognitive decline. Dementia ranks as the seventh leading cause of death, and its prevalence continues to rise in line with the aging global population.14,15 Although the exact etiology of AD remains unclear, several factors, including cholinergic dysfunction, amyloid-β (Aβ) deposition,16,17 tau protein aggregation,18 and oxidative stress,19 are major contributors to its pathophysiology. Advanced glycation end products (AGEs) significantly influence AD etiology. AGEs contribute to disease progression by enhancing the formation of amyloid plaques and tau filaments. In contrast, oxidative stress causes cellular damage by generating reactive oxygen species (ROS), thereby promoting the development of neurofibrillary tangles and amyloid plaques.20,21 Consequently, therapeutic strategies targeting oxidative stress and free-radical formation may help manage AD.22 The WHO has declared AD as a “global public health priority” as there is no permanent cure.23 Most current treatments rely on the cholinergic dysfunction theory, which attributes cognitive decline and memory impairment to the loss of cholinergic neurons and reduced acetylcholine (ACh) levels.24 The principal cholinesterase enzymes found in the human brain are acetylcholinesterase (AChE) and butyrylcholinesterase (BChE).25,26 In AD, brain AChE levels progressively decline, whereas BChE levels remain stable or may increase.24 Nowadays, cholinesterase inhibitors are used to elevate cholinergic activity.27 Modulating a single biochemical pathway may not be enough for effective therapy in Alzheimer's disease due to its complex nature and multiple pathways involved in its progression.28–30 Furthermore, free radicals and oxidative stress damage DNA, lipids, and proteins, contributing to the development of diabetes and Alzheimer's disease (AD), while antioxidants help mitigate these effects.31 Oxidative stress also promotes the formation of advanced glycation end products (AGEs), which are linked to the progression of both diseases. Diabetes and AD share common pathological mechanisms, including oxidative stress, inflammation, insulin resistance, mitochondrial dysfunction, amyloidosis, and cell death.32–34 Owing to the limited effectiveness of current treatments, multi-target neuroprotective agents are being explored, with heterocyclic compounds emerging as promising candidates due to their structural diversity and biological potential.35,36 Quinoline is an aromatic heterocyclic molecule with chemical properties comparable to those of benzene and pyridine, making it a valuable scaffold in medicinal chemistry.37,38 It serves as a lead structure for synthesizing numerous antimalarial medications, including mefloquine, amodiaquine, and primaquine.39,40 It is present in various medications for other diseases, including gatifloxacin, levofloxacin, bedaquiline, and clioquinol (Fig. 1A).41–43 Its derivatives are important in medicine and are marketed as drugs, exhibiting diverse pharmacological activities, including antioxidant,44 antiviral,45 antibacterial,46 antifungal,47 antiprotozoal,48 antitubercular,49 and antihypertensive effects.50 Thiourea, a nitrogen- and sulfur-containing organic compound, is highly versatile because its reactive nitrogen and sulfur atoms enable diverse chemical applications.51–53 Thiourea and its derivatives are important pharmaceutical agents with reported antiviral, anticancer, antiepileptic, antiallergic, antioxidant, and antidiabetic activities, among others.54 Rationale of the current study; (A) drugs containing the quinoline scaffold, (B) previously identified leads and a general representation of newly synthesized quinoline-based compounds. Quinoline remains a key scaffold in medicinal chemistry due to its pharmacological relevance and structural versatility. Although several quinoline-based α-amylase, α-glucosidase, acetylcholinesterase, and butyrylcholinesterase inhibitors have been reported (Fig. 1B),55–59 there remains a need for more effective inhibitors with fewer adverse effects. In light of the well-documented pharmacological potential of the quinoline moiety (Fig. 1), we designed a series of diversely substituted quinoline-based thiourea derivatives 1–41. These derivatives were subsequently assessed for their inhibitory activities against α-amylase, α-glucosidase, AChE, and BChE, as well as their antioxidant potential. The molecular design strategy focused on modifying multiple positions of the quinoline core to enhance functionalization and biological activity. Additionally, a variety of substituents were introduced at various positions on the aryl ring to investigate structure–activity relationships (SAR). Both electronic and steric factors were considered to optimize molecular properties and target interactions. This study aims to identify potential lead compounds for further research toward developing antidiabetic and anti-Alzheimer agents with complementary antioxidant activity. Results and discussion Chemistry Quinoline-based thiourea compounds 1–41 (Table 1) were synthesized by reacting 3-/5-/8-aminoquinoline with different substituted phenyl isothiocyanates in DCM at 0 °C (Fig. 2). Reaction progress was monitored by thin-layer chromatography using hexane/ethyl acetate (7 : 3). Structural elucidation of the synthesized compounds was achieved by EIMS, HR-EIMS, 1H- and 13C NMR analyses. Based on a literature review, only 10 of 41 compounds were reported.60–63 Table 1Synthesized quinoline-based thiourea derivatives 1–41 with diverse substitution patternsComp. No.RComp. No.R 1 7 2 8 3 9 4 10 5 11 6 12 13 20 14 21 15 22 16 23 17 24 18 25 19 26 34 27 35 28 36 29 37 30 38 31 39 32 40 33 41 Synthesized quinoline-based thiourea derivatives 1–41 with diverse substitution patterns Reaction scheme for the synthesis of quinoline-based thiourea derivatives 1–41. Biological assay In vitro inhibitory activities against α-amylase, α-glucosidase, AChE, and BChE All synthesized compounds 1–41 were evaluated for their in vitro inhibitory activities against α-amylase and α-glucosidase. The results revealed moderate to excellent inhibition of both enzymes, with IC50 values ranging from 18.36 to 43.91 µM for α-amylase and from 17.77 to 44.31 µM for α-glucosidase, compared with the reference inhibitor acarbose (IC50 = 16.98 ± 0.12 and 14.19 ± 0.06 µM, respectively). Compounds 1–41 were also assessed for in vitro AChE and BChE inhibitory activities. Relative to the reference inhibitor donepezil (IC50 = 1.49 ± 0.13; 2.39 ± 0.06 µM), the compounds demonstrated moderate to strong inhibition, with IC50 values ranging from 5.60 to 32.52 µM against AChE and from 6.99 to 33.67 µM against BChE (Table 2). Table 2 In vitro evaluation of α-amylase, α-glucosidase, AChE, and BChE inhibitory and antioxidant activities of quinoline-based thiourea derivatives 1–41Comp. No.α-Amylase inhibitory activityα-Glucosidase inhibitory activityAChE inhibitory activityBChE inhibitory activityDPPH scavenging activityABTS scavenging activityIC50 ± SEMa (µM)SC50 ± SEMa (µM)134.31 ± 0.1335.44 ± 0.2227.7 ± 0.0128.92 ± 0.1756.43 ± 0.1157.18 ± 0.08232.91 ± 0.1334.95 ± 0.0224.69 ± 0.0625.82 ± 0.0544.3 ± 0.1845.21 ± 0.14335.21 ± 0.0633.31 ± 0.0928.62 ± 0.0529.99 ± 0.1944.92 ± 0.2145.04 ± 0.21434.31 ± 0.3133.82 ± 0.1229.12 ± 0.0930.44 ± 0.1441.01 ± 0.3442.19 ± 0.19537.91 ± 0.0338.92 ± 0.1232.52 ± 0.0733.67 ± 0.1450.33 ± 0.1153.51 ± 0.12634.33 ± 0.0535.55 ± 0.0527.9 ± 0.1128.02 ± 0.2648.43 ± 0.1847.71 ± 0.19740.21 ± 0.0641.31 ± 0.09NAeNAe51.43 ± 0.0852.88 ± 0.07841.22 ± 0.0343.34 ± 0.1232.46 ± 0.0333.61 ± 0.1150.13 ± 0.5352.71 ± 0.11936.11 ± 0.1237.17 ± 0.2130.33 ± 0.0231.33 ± 0.1252.94 ± 0.2853.99 ± 0.211043.91 ± 0.1244.31 ± 0.0130.99 ± 0.0931.04 ± 0.0254.91 ± 0.1852.19 ± 0.311139.97 ± 0.0840.9 ± 0.130.99 ± 0.0932.04 ± 0.0257.04 ± 0.2858.91 ± 0.412NAeNAeNAeNAe62.43 ± 0.1864.71 ± 0.191332.11 ± 0.1331.19 ± 0.3220.91 ± 0.0821.99 ± 0.0644.04 ± 0.245.81 ± 0.121433.97 ± 0.0832.91 ± 0.1122.21 ± 0.1524.25 ± 0.0641.03 ± 0.1542.41 ± 0.141531.1 ± 0.1132.22 ± 0.2122.32 ± 0.1323.40 ± 0.0340.93 ± 0.0941.98 ± 0.161632.65 ± 0.0833.95 ± 0.0821.8 ± 0.1422.98 ± 0.1740.73 ± 0.1141.27 ± 0.051739.11 ± 0.1335.14 ± 0.2224.91 ± 0.0225.99 ± 0.0143.13 ± 0.1944.31 ± 0.021837.21 ± 0.0635.31 ± 0.0922.02 ± 0.1723.14 ± 0.1643.63 ± 0.0944.91 ± 0.221936.33 ± 0.1535.05 ± 0.224.02 ± 0.1126.14 ± 0.2656.93 ± 0.1557.01 ± 0.142031.98 ± 0.0832.08 ± 0.0225.33 ± 0.0224.33 ± 0.1241.63 ± 0.1742.81 ± 0.222130.01 ± 0.1331.34 ± 0.2122.17 ± 0.1625.17 ± 0.0642.13 ± 0.4544.22 ± 0.222235.31 ± 0.1236.61 ± 0.0128.01 ± 0.1229.33 ± 0.0244.43 ± 0.0546.42 ± 0.242330.97 ± 0.0831.9 ± 0.128.01 ± 0.1229.33 ± 0.0242.43 ± 0.1843.71 ± 0.1924NAeNAeNAeNAe59.04 ± 0.2860.91 ± 0.425NAeNAeNAeNAe61.63 ± 0.0964.91 ± 0.222629.61 ± 0.1228.17 ± 0.2116.5 ± 0.0317.89 ± 0.1352.83 ± 0.1153.92 ± 0.172720.01 ± 0.1419.84 ± 0.127.27 ± 0.158.01 ± 0.0525.15 ± 0.1527.56 ± 0.352820.01 ± 0.1421.94 ± 0.138.97 ± 0.299.7 ± 0.0429.13 ± 0.1930.42 ± 0.042928.21 ± 0.0629.31 ± 0.0919.42 ± 0.0420.54 ± 0.0239.43 ± 0.0140.48 ± 0.073023.58 ± 0.0921.88 ± 0.0610.17 ± 0.1911.07 ± 0.2630.04 ± 0.2831.91 ± 0.413118.36 ± 0.1217.77 ± 0.125.60 ± 0.186.99 ± 0.0223.92 ± 0.5124.06 ± 0.333231.22 ± 0.0130.02 ± 0.0519.41 ± 0.0820.76 ± 0.1135.43 ± 0.1836.18 ± 0.073326.11 ± 0.1227.17 ± 0.2118.41 ± 0.0819.76 ± 0.1140.54 ± 0.4841.99 ± 0.133424.11 ± 0.2322.22 ± 0.0210.02 ± 0.1711.14 ± 0.1634.43 ± 0.0135.81 ± 0.123528.21 ± 0.0626.31 ± 0.0914.97 ± 0.1915.7 ± 0.0634.73 ± 0.1135.27 ± 0.053627.51 ± 0.1329.19 ± 0.2215.17 ± 0.2616.17 ± 0.1139.91 ± 0.1138.01 ± 0.123725.01 ± 0.1826.08 ± 0.0214.86 ± 0.2315.16 ± 0.1339.83 ± 0.1540.92 ± 0.643833.31 ± 0.6234.61 ± 0.2127.01 ± 0.3228.13 ± 0.1243.63 ± 0.0545.72 ± 0.243935.33 ± 0.0536.55 ± 0.0523.02 ± 0.1724.14 ± 0.1643.9 ± 0.2844.8 ± 0.184036.11 ± 0.1232.17 ± 0.21NAeNAe42.92 ± 0.2144.04 ± 0.241NAeNAeNAeNAe62.43 ± 0.0160.81 ± 0.12Acarboseb16.98 ± 0.1214.19 ± 0.06————Donepezilc——1.49 ± 0.132.39 ± 0.06——Ascorbic acidd————18.28 ± 0.1520.79 ± 0.12aSEM = standard error of the mean.bAcarbose = standard of α-glucosidase and α-amylase.cDonepezil = standard of BChE and AChE.dAscorbic acid = standard of antioxidant activity.eNA = not active. In vitro evaluation of α-amylase, α-glucosidase, AChE, and BChE inhibitory and antioxidant activities of quinoline-based thiourea derivatives 1–41 SEM = standard error of the mean. Acarbose = standard of α-glucosidase and α-amylase. Donepezil = standard of BChE and AChE. Ascorbic acid = standard of antioxidant activity. NA = not active. Structure–activity relationship (SAR) for α-amylase, α-glucosidase inhibitory activities To facilitate structure–activity relationship (SAR) analysis, the synthesized compounds were grouped by the position of the amino group on the quinoline scaffold: 3-aminoquinoline, 5-aminoquinoline, and 8-aminoquinoline derivatives. Overall, the 8-aminoquinoline series consistently exhibited superior inhibitory activity against both α-amylase and α-glucosidase compared with the corresponding 3- and 5-aminoquinoline analogs, indicating that the position of the amino group plays a crucial role in enzyme inhibition. Compounds 13 (α-AMY, IC50 = 32.11 ± 0.13, α-GLU, 31.19 ± 0.32 µM) and 26 (IC50 = 29.61 ± 0.12, 28.17 ± 0.21 µM), bearing unsubstituted phenyl moieties, exhibited moderate inhibitory activity, with the 8-aminoquinoline derivative being slightly more potent than its 5-aminoquinoline counterpart. Furthermore, compound 30 (IC50 = 23.58 ± 0.09, 21.88 ± 0.06 µM), featuring an m-bromo substituent on the 8-aminoquinoline framework, exhibited improved activity. It suggests that the bromo substitution enhances inhibitory potential, likely due to stronger binding interactions with the enzyme's active site. However, no corresponding positional isomer was available for comparative activity analysis. At the same time, compounds with other halogen substitutions showed a similar trend against both enzymes. The compounds 1 (IC50 = 34.31 ± 0.13, 35.44 ± 0.22 µM) and 14 (IC50 = 33.97 ± 0.08, 32.91 ± 0.11 µM), with an o-fluoro substitution at the aryl ring of 3- and 5-aminoquinoline, exhibited lower activity when compared to compound 27 (IC50 = 20.01 ± 0.14, 19.84 ± 0.12 µM) with an 8-aminoquinoline. Inhibitory activity was further enhanced by incorporating another fluorine substituent at the para position in compound 31 (IC50 = 18.36 ± 0.12, 17.77 ± 0.12 µM), rendering it the most potent analog in the series. Other halogenated compound 28 (IC50 = 20.01 ± 0.14, 21.94 ± 0.13 µM) with an o-chloro analog of 8-aminoquinoline, emerged as the second most potent compound showing comparable activity to compound 27 however, when the same substitution was introduced on the aryl ring of 3-aminoquinoline in compound 2 (IC50 = 32.91 ± 0.13, 34.95 ± 0.02 µM), a significant decrease in inhibitory activity was observed. It suggests that ortho substitution in the 8-aminoquinoline framework provides optimal interaction with the enzyme's active site. Shifting the chloro substituent from the ortho to the meta position in compounds 3 (IC50 = 35.21 ± 0.06, 33.31 ± 0.09 µM), 15 (IC50 = 31.1 ± 0.11, 32.22 ± 0.21 µM), and 29 (IC50 = 28.21 ± 0.06, 29.31 ± 0.09 µM) resulted in a modest reduction in inhibitory activity (Fig. 3). Comparative analysis of structures and biological activities of compounds 1–3, 13–15, 26–31. Similarly, compounds 4 (IC50 = 34.31 ± 0.31, 33.82 ± 0.12 µM), 16 (IC50 = 32.65 ± 0.08, 33.95 ± 0.08 µM), and 32 (IC50 = 31.22 ± 0.01, 30.02 ± 0.05 µM) bearing dichloro substitutions at the ortho and meta positions exhibited reduced inhibitory activity against both enzymes. These findings underscore the critical influence of substituent positional orientation on inhibitory potency. Among all the compounds bearing electron-withdrawing groups, compound 34 (IC50 = 24.11 ± 0.23, 22.22 ± 0.02 µM) featuring 8-aminoquinoline with an o-chloro and p-nitro substitution exhibited remarkable inhibitory activity. However, relocating the amino group from the 8th to the 5th and 3rd positions on the quinoline ring, as in compounds 18 (IC50 = 37.21 ± 0.06, 35.31 ± 0.09 µM) and 6 (IC50 = 34.33 ± 0.05, 35.55 ± 0.05 µM), respectively, resulted in reduced activity. Furthermore, removal of the chloro substituent, as seen in compounds 5, 17, and 33 (37.91 ± 0.03, 38.92 ± 0.12; 39.11 ± 0.13, 35.14 ± 0.22; 26.11 ± 0.12, 27.17 ± 0.21), containing only a p-nitro group, resulted in a slight reduction in inhibitory potential (Fig. 4). Comparative analysis of structures and biological activities of compounds 4–6, 16–18, 32–34. Incorporation of a trifluoromethyl moiety at the meta position resulted in moderate to good inhibitory activity. Compound 7 (IC50 = 40.21 ± 0.06, 41.31 ± 0.09 µM), containing a 3-aminoquinoline core, exhibited comparatively lower activity. In contrast, compound 19 (IC50 = 36.33 ± 0.15, 35.05 ± 0.20 µM) with a 5-aminoquinoline scaffold showed improved inhibition. Notably, the 8-aminoquinoline-based compound 35 (IC50 = 28.21 ± 0.06, 26.31 ± 0.09 µM) demonstrated significantly enhanced inhibitory potency compared to compounds 7 and 19 (Fig. 5). Comparative analysis of structures and biological activities of compounds 7, 19, and 35. Moreover, among the alkoxy-substituted compounds, compound 37 (IC50 = 25.0 ± 0.18, 26.08 ± 0.02 µM) bearing an o-methoxy group at the 8-aminoquinoline moiety exhibited superior activity compared to compounds 9 (IC50 = 36.11 ± 0.12, 37.17 ± 0.21 µM) and 21 (IC50 = 30.01 ± 0.13, 31.34 ± 0.21 µM), which contain 3 and 5 aminoquinoline cores, respectively. Additionally, shifting the methoxy group from the ortho to the para position in compounds 10 (IC50 = 43.91 ± 0.12, 44.31 ± 0.01 µM), 22 (IC50 = 35.31 ± 0.12, 36.61 ± 0.01 µM), and 38 (IC50 = 33.31 ± 0.62, 34.61 ± 0.21 µM) led to a gradual decline in activity, indicating that the ortho substituent provides the most favorable interaction for inhibition. Conversely, introducing a p-ethoxy group in compounds 11 (IC50 = 39.97 ± 0.08, 40.9 ± 0.1 µM), 23 (IC50 = 30.97 ± 0.08, 31.9 ± 0.1 µM), and 39 (IC50 = 35.33 ± 0.05, 36.55 ± 0.05 µM) resulted in a slight increase in inhibitory potency compared to the p-methoxy analogs. Overall, the findings suggest that the o-methoxy group on 8-aminoquinoline offers the most effective inhibition against both enzymes. In addition, compound 8 (IC50 = 41.22 ± 0.03, 43.34 ± 0.12 µM) bearing an o-methyl group exhibited relatively low inhibitory activity in the 3-aminoquinoline series. However, its corresponding analog, compound 36 (IC50 = 27.51 ± 0.13, 29.19 ± 0.22 µM) in the 8-aminoquinoline series, showed an approximately 1.5-fold enhancement in activity. Likewise, compound 20 (IC50 = 31.98 ± 0.08, 32.08 ± 0.02 µM) demonstrated better inhibition than compound 8 but remained less effective than compound 36. These observations suggest that the o-methyl substitution in the 3-aminoquinoline scaffold hinders optimal enzyme interaction (Fig. 6). Comparative analysis of structures and biological activities of compounds 8–11, 20–23, and 36–39. Compound 40 (IC50 = 36.11 ± 0.12, 32.17 ± 0.21 µM), containing a naphthalene-2-yl substituent on the 8-aminoquinoline, displayed weak inhibitory activity. In contrast, compound 24, featuring a 5-aminoquinoline core, showed negligible inhibition, revealing that both the position and nature of substituents markedly influence the compound's activity. In addition, compounds 12, 25, and 41 bearing the cyclohexyl and diazenyl moieties were found to be inactive. SAR for AChE and BChE inhibitory activities A comprehensive SAR analysis was conducted to elucidate how different substituents affect inhibitory activity. The unsubstituted 5-aminoquinoline and 8-aminoquinoline derivatives 13 (AChE, IC50 = 20.91 ± 0.08 µM; BChE, 21.99 ± 0.06 µM) and 26 (IC50 = 16.50 ± 0.03 µM; 17.89 ± 0.13 µM), respectively, demonstrated moderate inhibitory potency. In contrast, the incorporation of an m-bromo substituent in compound 30 (IC50 = 10.17 ± 0.19 µM; 11.07 ± 0.26 µM) resulted in a pronounced enhancement of inhibitory activity compared with compounds 13 and 26. This observation suggests that m-bromo substitution strengthens binding interactions, thereby increasing inhibitory efficacy. Compounds bearing chloro and fluoro substituents demonstrated good to moderate inhibitory activity against both enzymes. Compounds 1 (IC50 = 27.70 ± 0.01, 28.92 ± 0.17 µM) and 14 (IC50 = 22.21 ± 0.15, 24.25 ± 0.06 µM), featuring an o-fluoro substituent on the aryl ring of 3- and 5-aminoquinoline, respectively, showed reduced activity compared with compound 27 (IC50 = 7.27 ± 0.15, 8.01 ± 0.05 µM), an 8-aminoquinoline derivative ranking second in potency within the series. Further enhancement of inhibitory activity was achieved by introducing an additional fluorine atom at the para position in compound 31 (IC50 = 5.60 ± 0.18, 6.99 ± 0.02 µM), rendering it the most potent compound of the series. Another halogenated derivative, compound 28 (IC50 = 8.97 ± 0.29, 9.70 ± 0.04 µM), containing an o-chloro substituent on the 8-aminoquinoline scaffold, exhibited activity comparable to that of compound 27. In contrast, the introduction of the same o-chloro substitution on 3-aminoquinoline in compound 2 (IC50 = 24.69 ± 0.06, 25.82 ± 0.05 µM) resulted in a marked reduction in inhibitory potency. These observations indicate that ortho substitution within the 8-aminoquinoline framework favors optimal interactions with the enzyme active site, whereas the 3-aminoquinoline scaffold is less accommodating. Furthermore, shifting the chloro substituent from the ortho to the meta position in compounds 3, 15, and 29 (IC50 = 28.62 ± 0.05, 29.99 ± 0.19; 22.32 ± 0.13, 23.40 ± 0.03; 19.42 ± 0.04, 20.54 ± 0.02 µM) led to a slight decline in inhibition (Fig. 7). Comparative analysis of structures and biological activities of compounds 1–3, 13–15, and 26–31. In contrast, dichloro substitution at the meta and ortho positions in compounds 4, 16, and 32 (IC50 = 29.12 ± 0.09, 30.44 ± 0.14; 21.80 ± 0.14, 22.98 ± 0.17; 19.41 ± 0.08, 20.76 ± 0.11 µM) resulted in diminished inhibitory activity against both enzymes. These findings further underscore the critical influence of substituent positional orientation on inhibitory potency. Among the electron-withdrawing derivatives, compound 34, bearing an 8-aminoquinoline core with o-chloro and p-nitro substitutions, exhibited the most pronounced inhibitory activity, with IC50 values of 10.02 ± 0.17 µM (AChE) and 11.14 ± 0.16 µM (BChE). In contrast, shifting the amino group from the 8-position to the 5- and 3-positions on the quinoline ring, as observed in compounds 18 (IC50 = 22.02 ± 0.17 and 23.14 ± 0.16 µM) and 6 (IC50 = 27.90 ± 0.11 and 28.02 ± 0.26 µM), respectively, led to a notable reduction in inhibitory potency. Furthermore, elimination of the chloro substituent, yielding compounds 5, 17, and 33 containing only a p-nitro group (IC50 = 32.52 ± 0.07, 33.67 ± 0.14; 24.91 ± 0.02, 25.99 ± 0.01; 18.41 ± 0.08, 19.76 ± 0.11 µM), resulted in a slight decline in activity compared with compounds 6, 18, and 34. These findings suggest that the 8-aminoquinoline scaffold is particularly favorable for optimal interactions within the enzyme active site. Introduction of an m-trifluoromethyl substituent afforded moderate to good inhibitory effects. Compound 7, based on a 3-aminoquinoline framework, was found to be inactive, whereas compound 19 (IC50 = 24.02 ± 0.11 and 26.14 ± 0.26 µM), featuring a 5-aminoquinoline core, demonstrated improved inhibition. Notably, the 8-aminoquinoline-based compound 35 (IC50 = 14.97 ± 0.19 and 15.70 ± 0.06 µM) revealed significantly better inhibition compared to compounds 7 and 19 (Fig. 8). Comparative analysis of structures and biological activities of compounds 4–7, 16–19, and 32–35. Furthermore, within the alkoxy-substituted series, compound 37, featuring an o-methoxy substituent on the 8-aminoquinoline scaffold, displayed superior inhibitory activity (IC50 = 14.86 ± 0.23 and 15.16 ± 0.13 µM) compared with compound 9 (IC50 = 30.33 ± 0.02 and 31.33 ± 0.12 µM) and compound 21 (IC50 = 22.17 ± 0.16 and 25.17 ± 0.06 µM), which possess 3- and 5-aminoquinoline cores, respectively. In addition, shifting the methoxy group from the ortho to the para position, as observed in compounds 10, 22, and 38 (IC50 = 30.99 ± 0.09 and 31.04 ± 0.02; 28.01 ± 0.12 and 29.33 ± 0.02; 27.01 ± 0.32 and 28.13 ± 0.12 µM), resulted in a progressive reduction in inhibitory potency, indicating that ortho substitution is most favorable for enzyme inhibition. Conversely, incorporation of a p-ethoxy group in compounds 11, 23, and 39 (IC50 = 30.99 ± 0.09 and 32.04 ± 0.02; 28.01 ± 0.12 and 29.33 ± 0.02; 23.02 ± 0.17 and 24.14 ± 0.16 µM) afforded inhibitory activities comparable to their corresponding p-methoxy analogs. Collectively, these results highlight the o-methoxy substitution on the 8-aminoquinoline framework as the most effective motif for dual enzyme inhibition. Additionally, compound 8, bearing an o-methyl group within the 3-aminoquinoline series, exhibited relatively weak inhibition (IC50 = 32.46 ± 0.03 and 33.61 ± 0.11 µM). In contrast, its 8-aminoquinoline analog, compound 36, demonstrated an approximately two-fold enhancement in activity (IC50 = 15.17 ± 0.26 and 16.17 ± 0.11 µM). Compound 20 (IC50 = 25.33 ± 0.02 and 24.33 ± 0.12 µM) showed improved inhibition relative to compound 8 but remained less potent than compound 36. These findings suggest that o-methyl substitution on the 3-aminoquinoline scaffold may impede optimal enzyme–ligand interactions, whereas the 8-aminoquinoline framework better accommodates such substitutions. Compounds 12, 24, 25, 40, and 41, functionalized with naphthalen-2-yl, cyclohexyl, and diazenyl groups on 8-, 5-, or 3-aminoquinoline cores, showed no detectable inhibitory activity (Fig. 9). Comparative analysis of structures and biological activities of compounds 8–11, 20–23, and 36–39. Enzyme kinetics study Kinetic studies for α-amylase inhibition For kinetic investigations, six quinoline derivatives 27, 31, 30, 28, 34, and 35 were chosen due to their comparatively lower IC50 values (18.36–28.21 µM). The studies used starch at different concentrations (0.175, 0.35, 0.7, and 1.40 mM), while α-amylase inhibitor concentrations were varied (0, 0.625, 1.25, and 2.5 µM).65 The reaction velocities were determined for each substrate and inhibitor concentration, and the inhibition mechanism was analyzed using SigmaPlot 15.0 software.66 The mode of enzyme inhibition was determined using software based on reaction velocity data. Kinetic evaluation indicated that all selected derivatives acted as competitive inhibitors (Table 3). Lineweaver–Burk plot, the reciprocal of reaction velocity (1/V) against the reciprocal of substrate concentration (1/[S]) to assess the influence of inhibitors on the Michaelis constant (Km) and maximum velocity (Vmax), was used further to analyze the inhibition pattern of α-amylase.67 The calculated Km and Vmax values for the six derivatives ranged from 0.15 to 35.0 mM and 210.2 to 236.4 µM min−1 mg−1, respectively (Fig. 10A). Moreover, inhibition constants (Ki) were validated using Dixon plots, which plot the reciprocal of the reaction rate against varying inhibitor concentrations, yielding values of 3.1–3.7 µM for all compounds (Fig. 10B). As expected for competitive inhibition, only Km values were affected, while Vmax remained unchanged. The increase in Km, along with no change in Vmax, confirms that these compounds act as competitive inhibitors. Table 3Mode of α-amylase inhibition by compounds 27, 31, 30, 28, 34, and 35, and acarbose, including their Vmax,Km, and Ki parametersInhibitors V max (µM min−1 mg−1) K m (mM) K i (µM)Type of inhibition27210.2 ± 2.024.1 ± 0.023.4 ± 0.02Competitive31221.7 ± 3.640.29 ± 0.013.1 ± 0.02Competitive30220.5 ± 1.0320.9 ± 0.023.4 ± 0.01Competitive28236.4 ± 2.100.15 ± 0.023.7 ± 0.01Competitive34227.4 ± 1.1235.0 ± 0.023.7 ± 0.01Competitive35230.6 ± 3.1625.4 ± 0.023.7 ± 0.01CompetitiveAcarbose189.0 ± 2.056.5 ± 0.013.0 ± 0.01Competitive Mode of α-amylase inhibition by compounds 27, 31, 30, 28, 34, and 35, and acarbose, including their Vmax,Km, and Ki parameters (A) Lineweaver–Burk plot; (B) Dixon plot of compound 31. Kinetic studies for α-glucosidase inhibition Six quinoline derivatives 27, 31, 30, 28, 34, and 35 were selected for further study due to their relatively low IC50 values (15.27–24.13 µM). Kinetic investigations were performed using starch at different concentrations (0.175, 0.35, 0.7, and 1.40 mM), while the α-amylase inhibitor was applied at concentrations of 0, 0.625, 1.25, and 2.5 µM.65 The corresponding reaction velocities were determined for each substrate and inhibitor level, and the inhibition mechanism was assessed using SigmaPlot 15.0 software.66 Kinetic studies indicate that the tested compounds act as non-competitive inhibitors, as summarized in Table 4. The inhibition pattern was determined using Lineweaver–Burk plots67 by plotting the reciprocal of reaction velocity against the reciprocal of substrate concentration to evaluate the effects on Vmax and Km. The Km and Vmax values ranged from 0.30 to 0.37 mM and 55.2 to 244.8 µM min−1 mg−1, respectively (Fig. 11A). Dixon plots were used to calculate Ki by plotting the reciprocal of the reaction rate versus inhibitor concentration. The Ki values for the tested compounds ranged from 10.4 to 10.8 µM (Fig. 11B). In non-competitive inhibition, only Vmax is affected while Km remains unchanged. The observed reduction in Vmax, together with the negligible effect on Km, indicates that these compounds act through a non-competitive inhibition mechanism. Table 4Mode of α-glucosidase inhibition by compounds 27, 31, 30, 28, 34, and 35, and acarbose, including their Vmax,Km, and Ki parametersInhibitors V max (µM min−1 mg−1) K m (mM) K i (µM)Type of inhibition27150.4 ± 10.540.32 ± 0.0210.5 ± 0.2Non-competitive31240.2 ± 8.040.37 ± 00.110.4 ± 0.6Non-competitive3055.2 ± 10.40.32 ± 00.210.8 ± 1.2Non-competitive28185.4 ± 12.020.35 ± 00.210.7 ± 0.1Non-competitive34244.8 ± 9.920.30 ± 00.210.7 ± 0.5Non-competitive3585.4 ± 4.050.35 ± 00.210.7 ± 0.8Non-competitiveAcarbose200.2 ± 2.00.20 ± 0.015.0 ± 0.1Non-competitive Mode of α-glucosidase inhibition by compounds 27, 31, 30, 28, 34, and 35, and acarbose, including their Vmax,Km, and Ki parameters (A) Lineweaver–Burk plot; (B) Dixon plot of compound 31. Kinetic studies for AChE inhibition For kinetic evaluation, six quinoline derivatives (27, 31, 30, 28, 34, and 35) were chosen due to their relatively low IC50 values (5.60–14.97 µM). AChE inhibitor concentrations were 0, 0.625, 1.25, and 2.50 µM, and the substrate was acetylthiocholine iodide (ATCI) at 0.175, 0.35, 0.70, and 1.40 mM. Reaction velocities were determined to investigate enzyme kinetics, and SigmaPlot 15.0 software was used to assess the inhibition mechanisms.68,69 Kinetic studies revealed that the selected compounds act as non-competitive inhibitors, summarized in Table 5. The inhibition pattern of AChE was analyzed using Lineweaver–Burk plots,70 which plot 1/V against 1/[S] to determine the effect of the inhibitors on Vmax and Km. For all six compounds, Vmax values varied from 86.2 to 333.7 µM min−1 mg−1, while values of Km remained nearly constant (0.91–0.95 mM), as illustrated in Fig. 12A. Plotting the reciprocal of the reaction rate against varying inhibitor concentrations enabled calculation of Ki values using Dixon plots. The calculated Ki values ranged from 9.0 to 9.6 µM (Fig. 12B). Consistent with non-competitive inhibition, Vmax decreased without a significant change in Km. Table 5Mode of AChE inhibition by compounds 27, 31, 30, 28, 34, and 35, and donepezil, including their Vmax,Km, and Ki parametersInhibitors V max (µM min−1 mg−1) K m (mM) K i (µM)Type of inhibition27221.3 ± 4.030.92 ± 0.029.2 ± 0.2Non-competitive31333.7 ± 2.500.95 ± 0.019.1 ± 0.2Non-competitive30160.4 ± 1.200.93 ± 0.029.2 ± 0.1Non-competitive2820.2 ± 2.300.92 ± 0.029.6 ± 0.1Non-competitive34206.2 ± 3.450.91 ± 0.029.0 ± 0.1Non-competitive3586.2 ± 2.120.92 ± 0.029.2 ± 0.1Non-competitiveDonepezil120.1 ± 2.040.90 ± 0.019.0 ± 0.1Non-competitive Mode of AChE inhibition by compounds 27, 31, 30, 28, 34, and 35, and donepezil, including their Vmax,Km, and Ki parameters (A) Lineweaver–Burk plot; (B) Dixon plot of compound 31. Kinetic studies for BChE inhibition Six quinoline derivatives 27, 31, 30, 28, 34, and 35 were selected for kinetic studies owing to their comparatively low IC50 values (6.99–15.70 µM). Butyrylthiocholine iodide (BTCI) was used as the substrate at different concentrations (0.175, 0.35, 0.70, and 1.40 mM), while the BChE inhibitor was tested at concentrations of 0, 0.625, 1.25, and 2.50 µM. Inhibition kinetics were analyzed using SigmaPlot 14.0, and reaction rates were calculated accordingly.68,69 Kinetic evaluation of the reaction velocity data revealed that all tested compounds exhibit mixed-type inhibition (Table 6). The inhibition pattern was assessed by plotting the reciprocal of reaction velocity against the reciprocal of substrate concentration to determine their effects on Vmax and Km.70 The Km and Vmax values varied from 3.14 to 9.14 mM and 110.5 to 227.0 µM min−1 mg−1, respectively (Fig. 13A). As expected for mixed inhibition, Vmax decreased while Km increased, indicating that the inhibitor interacts with both the enzyme-substrate complex and the free enzyme. The inhibitor's binding alters the enzyme's affinity, thereby diminishing effective substrate binding. Ki values ranged from 0.30 to 0.36 µM (Fig. 13B), indicating strong inhibitor-enzyme interactions, as determined by plotting the reciprocal of reaction rate against varying compound concentrations. The α values ranged from 6.2 to 12.0, confirming mixed inhibition and suggesting dominant competitive inhibition. Table 6Mode of BChE inhibition by compounds 27, 31, 30, 28, 34, and 35, and donepezil, including their Vmax,Km, and Ki parametersInhibitors V max (µM min−1 mg−1) K m (mM) K i (µM)Alpha (α)Type of inhibition27201.2 ± 2.47.26 ± 00.20.31 ± 0.0212.0 ± 0.6Mixed type (competitive)31227.0 ± 10.53.14 ± 00.10.36 ± 0.028.8 ± 0.2Mixed type (competitive)30122.4 ± 8.68.08 ± 00.20.30 ± 0.016.2 ± 0.6Mixed type (competitive)28220.5 ± 4.27.83 ± 00.20.33 ± 0.018.3 ± 0.4Mixed type (competitive)34110.5 ± 1.48.03 ± 00.20.35 ± 0.0110.3 ± 0.8Mixed type (competitive)35180.5 ± 2.29.14 ± 00.20.32 ± 0.016.3 ± 0.3Mixed type (competitive)Donepezil100.6 ± 2.35.0 ± 00.10.30 ± 0.018.5 ± 0.2Mixed type (competitive) Mode of BChE inhibition by compounds 27, 31, 30, 28, 34, and 35, and donepezil, including their Vmax,Km, and Ki parameters (A) Lineweaver–Burk plot; (B) Dixon plot of compound 31. Docking studies Molecular docking was performed to investigate the binding interactions between the synthesized compounds and the selected target proteins. The docking simulations utilized the crystal structures of α-amylase (PDB ID: 1B2Y), α-glucosidase (PDB ID: 3WY1), AChE (PDB ID: 7E3H), and BChE (PDB ID: 5DYW). For comparative purposes, the reference inhibitor acarbose was also docked alongside the tested compounds. The docking scores, hydrogen-bonding interactions with specific amino acid residues, and corresponding bond lengths are summarized in Tables S7–S10 and correlated with the IC50 values of the respective target enzymes. Table 7ADME/drug-likeness prediction of the most active compounds 27, 28, 31, and the standard drugADME/DRUG-LIKENESSCOMPOUNDSDONEPEZILACARBOSE272831 MOLECULAR PROPERTIES Lipinski's rule of fiveSuitableViolatedSuitableSuitableSuitablePAINS # alerts00000Brenk # alerts01111Synthetic accessibility3.367.342.662.682.68TPSA (Å2)38.77321.1769.0469.0469.04Bioavailability score (F)0.550.170.550.550.55 METABOLISM CYP2D6 substrateNoNoNoYesNoCYP3A4 substrateYesNoYesYesNoCYP1A2 inhibitorNoNoYesYesYesCYP2C19 inhibitorNoNoYesYesYesCYP2C9 inhibitorNoNoNoNoNoCYP2D6 inhibitorYesNoNoNoNoCYP3A4 inhibitorYesNoYesNoNo TOXICITY AMES toxicityMutagenNon-mutagenMutagenMutagenMutagenMax. tolerated dose (human)0.0950.5380.2570.3740.14hERG I inhibitorNoNoNoNoNohERG II inhibitorYesYesYesYesYesHepatotoxicityYesNoYesNoYes T. Pyriformis toxicity0.9310.2850.780.8790.645Minnow toxicity−1.36814.6340.5150.568−0.324Carcino_mouseNegativeNegativePositivePositivePositiveCarcino_ratNegativeNegativePositiveNegativePositiveSkin sensitizationNoNoNoNoNo ABSORPTION Water solubilitySolubleSolubleSolubleSolubleSolubleLipophilicity (XLOGP3)4.28−8.534.004.524.10HIA97.9513530.00000095.59374495.96608695.604159Caco-255.51459.4444835.884144.315738.9098Skin permeability−3.04165−5.17615−2.94699−2.7083−3.13536P-glycoprotein substrateYesYesYesYesYesP-glycoprotein I inhibitorYesNoNoNoNoP-glycoprotein II inhibitorYesNoNoNoNo EXCERTION Total clearance0.9980.5050.0340.1250.007Renal OCT2 substrateYesNoNoNoNo DISTRIBUTION CNS permeability−1.419−7.15−0.939−0.89−0.96BBB permeability0.349−2.990.3770.4950.474VDss (human)1.262−0.854−0.0580.103−0.049Fraction unbound (human)0.0220.5330.110.0940.128 ADME/drug-likeness prediction of the most active compounds 27, 28, 31, and the standard drug Molecular docking interactions of the quinoline derivatives with α-amylase Using the crystal structure of pancreatic α-amylase (PDB ID: 1B2Y), molecular docking of the synthesized compounds was carried out. The reference acarbose, an oligosaccharide, exhibited multiple hydrogen-bonding interactions within the enzyme's active site. Specifically, amino acid residues Leu162, Gln63, Glu233, Lys200, Asp300, Gly306, and His305 interacted with the acarbose moiety, exhibiting bond distances of 2.86, 3.73, 1.96, 2.68, 2.75, 2.27, and 3.20 Å, respectively. The highest-ranked docking conformation of acarbose showed a binding score of −8.43. Compounds 27 and 31 demonstrated hydrophobic interactions with key active-site residues, namely Ile235, Trp59, Trp58, and Tyr62. Compound 30 formed hydrophobic contacts with Trp59, Trp58, Ile235, and Thr163. In contrast, compound 28 established a hydrogen bond with Asp300 at a bond distance of 2.58 Å, along with hydrophobic interactions involving Trp59, Trp58, Tyr151, Tyr62, and Ile235. Compounds 23 and 35, which exhibited comparatively low IC50 values, achieved the highest-ranked docking poses with scores of −5.93 and −5.27, respectively. Detailed interaction analysis showed that compound 23 formed hydrophobic interactions with Tyr62, Trp59, and Lys200 of α-amylase, along with hydrogen bonds involving Gln63 and His305 at bond lengths of 2.47 and 2.97 Å, respectively. Similarly, compound 35 formed a hydrogen bond with Gln63 at 3.54 Å and exhibited hydrophobic interactions with Trp59 and Leu162. Among the active-site residues, Gln63, Lys200, and Asp300 were most frequently involved in hydrogen bonding, whereas Leu162 and Trp59 predominantly participated in hydrophobic interactions. These findings suggest that these residues play a critical role in stabilizing ligand binding within the α-amylase active pocket (Fig. 14 and Table S1). Docking poses illustrating the interactions of α-amylase active site residues with (A) 27, (B) 31, (C) 30, (D) 28, (E) 23, (F) 35, (G) control acarbose. Molecular docking interactions of the quinoline derivatives with α-glucosidase The crystal structure of pancreatic α-glucosidase (PDB ID: 3WY1) was used to perform molecular docking investigations of the synthesized compounds. Acarbose, the reference oligosaccharide inhibitor, showed several hydrogen bond interactions in the α-glucosidase active site. In particular, residues Arg200, Asp62, Asp202, Thr203, Gly228, Glu271, Asn301, His332, Tyr389, Asp333, and Arg400 established hydrogen bonds with acarbose ring atoms at bond distances of 2.19, 3.21, 2.13, 2.19, 2.99, 2.67, 2.11, 2.70, 2.56, 2.65, 2.43, 2.00, 1.90, and 3.09 Å, respectively. Acarbose's top-ranked docking pose showed a binding score of −7.94. Compounds 27 and 31 exhibited comparatively low IC50 values and ranked among the highest-scoring docking poses, with binding scores of −6.93 and −7.33, respectively. A detailed interaction study revealed that compound 27 formed hydrogen bonds with Glu271 and Arg200 of α-glucosidase at bond distances of 3.01 and 2.30 Å, respectively. Compound 31 established hydrogen-bonding interactions with Asp333, Arg400, and Tyr389 with corresponding distances of 3.06, 3.46, and 3.18 Å, respectively. For compound 30, hydrophobic interactions were primarily observed with residues Phe166, Ile146, Phe206, Phe297, and Ala229. Compound 28 formed a hydrogen bond with Asp333, while Ile146, Phe166, Thr203, Ala229, and Tyr235 participated in hydrophobic contacts. Similarly, compound 34 displayed hydrogen bonding with Tyr389 and Asp333, along with hydrophobic interactions involving Phe147, Phe166, Phe206, Phe297, Ile146, Thr203, Ala229, Glu271, and Tyr389. In the case of compound 35, key residues including Ile146, Tyr389, Thr203, Phe147, Phe166, Phe206, Phe297, Ala229, and Glu271 contributed predominantly to hydrophobic stabilization within the binding pocket. Overall, the docking scores of the evaluated compounds ranged from −6 to −7. Among the α-glucosidase active site residues, Tyr389, Gly228, and Asp333 most frequently participated in hydrogen bond formation, whereas Ile146, Phe166, Thr203, Thr226, Ala229, Tyr235, and Phe297 predominantly contributed to hydrophobic interactions. Collectively, these residues play a critical role in stabilizing ligand binding within the α-glucosidase active site (Fig. 15 and Table S2). Docking poses illustrating the interactions of α-glucosidase active site residues with (A) 27, (B) 31, (C) 30, (D) 28, (E) 34, (F) 35, (G) control acarbose. Molecular docking interactions of the quinoline derivatives with AChE Docking analyses of the synthesized derivatives were conducted utilizing the crystal structure of pancreatic AChE (PDB ID: 7E3H). The reference inhibitor, donepezil, showed several hydrogen-bond interactions within the enzyme's active site. Specifically, the ligand and residues Tyr124 and Phe295 established hydrogen bonds at 2.80 and 2.26 Å, respectively. Donepezil's top-ranked docking pose has a binding score of −8.73. In addition, Tyr341, Trp86, and Trp286 contributed to hydrophobic interactions within the binding pocket. Compounds 27, 31, and 30 established hydrogen-bond interactions with key residues, including Tyr124, Tyr337, Tyr341, and Asp74, whereas Asp74, Trp86, Phe338, Trp286, and Tyr337 predominantly provided hydrophobic contacts. Compound 28 interacted hydrophobically with Tyr341, Trp86, Phe297, and Phe338. Similarly, compound 34 formed a hydrogen bond with Tyr124, whereas Phe297 and Phe338 participated in hydrophobic interactions within the binding pocket. Compounds 26 and 35 exhibited the lowest IC50 values and attained top-ranked docking conformations with binding scores of −7.11 and −7.38, respectively. While Trp86, Tyr337, and Phe338 were primarily involved in hydrophobic interactions, compound 26 formed hydrogen bonds with Asp74 and Tyr124 at distances of 2.39 and 3.77 Å, respectively. Similarly, derivative 35 formed hydrogen bonds with Asp74 and Tyr124 at 3.01 and 3.32 Å, respectively. In addition, Tyr337, Trp86, and Trp286 contributed to hydrophobic stabilization within the active site. Among the AChE residues, Asp74 and Tyr124 were frequently involved in hydrogen bond formation, whereas Tyr341, Tyr337, Trp286, and Phe338 predominantly participated in hydrophobic interactions. Thus, these residues are thought to be crucial for preserving the AChE binding pocket's structural integrity (Fig. 16 and Table S3). Docking poses illustrating the interactions of AChE active site residues with (A) 27, (B) 31, (C) 30, (D) 34, (E) 26, (F) 35, (G) control donepezil. Molecular docking interactions of the quinoline derivatives with BChE Using the crystal structure of pancreatic BChE (PDB ID: 5DYW), docking studies of the synthesized derivatives were conducted. The reference inhibitor (donepezil) exhibited prominent hydrophobic interactions with Trp82, Phe329, Tyr332, and Tyr40, and the binding score of the top-ranked docking pose was −8.64. Compound 27 formed a hydrogen bond with Ser198, while Leu286 and Val288 contributed to hydrophobic interactions. Similarly, compound 31 demonstrated hydrophobic contacts with Val288 and Trp430. Compound 28 established hydrogen bonds with Gly117 and Ser198, along with hydrophobic interactions involving Asp70, Trp82, and Val288. Compound 34 displayed hydrogen bonding with Thr120 and hydrophobic interactions with Val288. In the case of compound 35, a hydrogen bond was observed with Asp70, whereas Trp231 was involved in hydrophobic stabilization within the binding pocket. Compounds 30 and 20, which exhibited comparatively low IC50 values, achieved top-ranked docking conformations with binding scores of −7.41 and −7.72, respectively. Detailed interaction analysis revealed that compound 30 formed a hydrogen bond with Asp70 of BChE, while a hydrophobic interaction was observed with Trp231. Compound 20 formed multiple hydrogen-bond interactions with Trp82, Gly117, Ser198, and Trp430 at distances of 3.01, 3.46, 2.17, and 3.02 Å, respectively. Moreover, hydrophobic contacts were identified with Trp82, Trp231, Val288, Ala328, and Phe329. Among the BChE active site residues, Gly117 and Ser198 were most frequently involved in hydrogen bond formation, whereas Trp82, Val288, Ala328, and Phe329 predominantly contributed to hydrophobic interactions. Accordingly, these residues are considered crucial for maintaining ligand binding within the BChE active site (Fig. 17 and Table S4). Conclusively, a good correlation was found between the IC50 values of compounds and docking scores of the selected target proteins (Fig. 18). Docking poses illustrating the interactions of butyrylcholinesterase active site residues with (A) 27, (B) 31, (C) 28, (D) 34, (E) 30, (F) 20, (G) control donepezil. Correlation plots illustrating the relationship between IC50 values and docking scores of the selected target proteins. In vitro antioxidant activities Antioxidant activity was evaluated using the DPPH and ABTS radical scavenging assays. The DPPH assay is based on the reduction of the stable purple DPPH radical to a yellow-colored form in the presence of an antioxidant, which is quantified by a decrease in absorbance at 517 nm. Antioxidant capacity was expressed as SC50 (µM), the concentration required to neutralize 50% of free radicals.64 Among the compounds, compound 31 exhibited the lowest SC50 values (23.92 ± 0.51 and 24.06 ± 0.33 µM), indicating the highest antioxidant potency. Quinoline-based thiourea derivatives 27, 28, 30, 31, 34, and 35 demonstrated significant radical scavenging activity against both DPPH and ABTS, with SC50 values ranging from 23.92–62.43 µM and 24.06–64.91 µM, respectively. Compound 31 emerged as the most effective analog when compared with the standard antioxidant ascorbic acid (SC50 = 18.28 ± 0.15 and 20.79 ± 0.12 µM). Slightly reduced activity was observed for compounds 27 (SC50 = 25.15 ± 0.15, 27.56 ± 0.35 µM), 28 (SC50 = 29.13 ± 0.19, 30.42 ± 0.04 µM), 30 (SC50 = 30.04 ± 0.28, 31.91 ± 0.41 µM), 34 (SC50 = 34.43 ± 0.01, 35.81 ± 0.12 µM), and 35 (SC50 = 34.73 ± 0.11, 35.27 ± 0.05 µM) relative to compound 31. All other derivatives showed moderate to weak activity compared to ascorbic acid (Table 2). In silico drug-likeness and ADME studies The in silico drug-likeness and ADME profiles (Table 7) of the three most potent compounds (27, 28, and 31) have been compared with those of donepezil and acarbose. All compounds and donepezil follow Lipinski's rule of five, though acarbose violates the rule, suggesting low oral drug-likeness. There were no pain alerts found for any of these compounds, though one Brenk alert was observed for each compound. Donepezil exhibited no Brecken alerts. These compounds had a lower synthetic accessibility score (2.66–2.68) than acarbose (7.34), suggesting easier synthesis. All indicated high bioavailability scores (F = 0.55) and moderate TPSA (69.04 Å2), comparable to donepezil and better than acarbose. According to metabolic standards, compound 28 acted as a CYP2D6 inhibitor, and compounds 27 and 28 were CYP3A4 substrates. Compound 31 did not exhibit substrate liability. All compounds inhibited CYP2C19 and CYP1A2, while compound 27 also inhibited CYP3A4, suggesting potential drug–drug interaction risk. Toxicity examination indicated AMES positivity for compounds 27, 28, and 31, unlike acarbose. Maximum tolerable doses were moderate (0.14–0.374). All showed hERG II inhibition, but none inhibited hERG I. Carcinogenicity and hepatotoxicity were anticipated for compounds 27 and 31. However, compound 28 was carcinogenic only in mice and did not exhibit hepatotoxicity. Skin sensitization was not predicted. All synthetic compounds were water-soluble, moderately lipophilic (XLOGP3 = 4.00–4.52), and showed greater Caco-2 permeability and excellent intestinal absorption (>95%) than acarbose. None of the compounds showed P-gp inhibition, even though they possessed P-gp substrates, unlike donepezil. Compounds 27 and 28 displayed higher total clearance than compound 31, which had low clearance, indicating prolonged systemic exposure. Distribution parameters indicated improved BBB and CNS permeability, with balanced systemic distribution compared to the reference drugs. Although the most active compounds exhibited promising inhibitory activity against the tested enzymes, in silico toxicity assessment indicated AMES positivity for some derivatives, suggesting a potential mutagenic risk. This finding may limit their immediate suitability as lead candidates and highlights the need for further structural optimization to improve their safety profile. It is important to note that AMES predictions are computational and should be interpreted cautiously until confirmed by experimental mutagenicity studies. Nevertheless, the observed biological activity and favorable binding interactions provide a valuable basis for future optimization efforts aimed at retaining potency while reducing potential toxicological liabilities. Conclusion A library of quinoline-based thiourea derivatives 1–41 was successfully synthesized and screened for enzyme inhibitory activities associated with diabetes mellitus, Alzheimer's disease, and oxidative stress. The evaluated compounds displayed moderate to strong inhibition of α-amylase, α-glucosidase, AChE, and BChE in the micromolar range. Among them, compounds 27–31 and 33–37 exhibited pronounced inhibitory effects against α-amylase and α-glucosidase compared to the reference standard. Furthermore, compounds 27, 28, 30, 31, 34, 35, and 37 demonstrated notable inhibitory activity against AChE and BChE, as well as appreciable DPPH radical-scavenging potential. Enzyme kinetic studies elucidated the inhibition mechanisms, while molecular docking analyses supported key interactions between the synthesized ligands and the active-site residues of the target enzymes. Overall, these results underscore the promise of the newly synthesized quinoline-thiourea hybrids as potential multi-target therapeutic candidates for managing diabetes mellitus and Alzheimer's disease, with the added benefit of antioxidant activity. Experimental Materials and methods All reagents were procured from Sigma-Aldrich (USA). Thin-layer chromatography (TLC) was performed on precoated silica gel aluminum plates (GF-254; Merck, Germany). The chromatographic spots were visualized under ultraviolet light at 254 and 366 nm or by exposure to iodine vapors. Electron impact mass spectra were recorded using MAT 113D and MAT 312 mass spectrometers (JEOL JMS-600H, Japan). Nuclear magnetic resonance (NMR) spectra were obtained on a Bruker Avance Neo spectrometer (Bruker, Switzerland) operating at 400 MHz. Chemical shifts were reported in parts per million (ppm), while coupling constants (J) were expressed in hertz (Hz). Melting points of the synthesized compounds were determined using a Stuart® SMP10 melting point apparatus (Büchi M-560, Switzerland). General procedure for the synthesis of quinoline derivatives (1–41) In a 100 mL round-bottom flask, 3-, 5-, or 8-aminoquinoline (1 mmol) was reacted with the appropriate phenyl isothiocyanate (1 mmol) in dichloromethane (10 mL) under stirring at 0 °C for 6–7 h. The reaction progress was monitored by thin-layer chromatography (TLC) using a hexane-ethyl acetate solvent system. Upon completion, the precipitated products were collected by filtration, washed with hot hexane, and crystallized from ethanol to afford the pure compounds. Spectral data of synthetic compounds 1-(2-Fluorophenyl)-3-(quinolin-3-yl)thiourea (1) Yield: 71% (210.8 mg); yellow solid; MP: 170–172 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.21 (s, 1H, NHb), 9.81 (s, 1H, NHa), 8.93 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.42 (d, 1H, J4,2 = 2.0 Hz, H-4), 7.98 (d, 1H, J5,6 = 8.4 Hz, H-5), 7.94 (d, 1H, J8,7 = 7.6 Hz, H-8), 7.70 (t, 1H, J7,6/7,8 = 7.2 Hz, H-7), 7.61 (m, 2H, H-6, H-6′), 7.28 (m, 2H, H-3′, H-5′), 7.21 (m, 1H, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 181.5, 157.4, 155.5, 148.7, 144.7, 133.3, 128.7, 128.6, 128.5, 128.0, 127.7, 126.9, 126.7, 124.3, 116.0, 115.8; EI-MS m/z (% rel. abund.): 297 (M+, 6), 263 (42), 186 (100), 144 (68), 128 (70), 111 (89); HREI-MS m/z: calcd for C16H12N3FS [M]˙+ [297.0743], found [297.0736]. 1-(2-Chlorophenyl)-3-(quinolin-3-yl)thiourea (2) Yield: 69% (215.9 mg); off-white solid; MP: 135–137 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.22 (s, 1H, NHb), 9.79 (s, 1H, NHa), 8.95 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.44 (br s, 1H, H-4), 7.98 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.94 (d, 1H, J8,7 = 8.0 Hz, H-8), 7.69 (t, 1H, J6,5/6,7 = 7.2 Hz, H-6), 7.60 (m, 2H, H-7, H-6′), 7.54 (d, 1H, J3′,4′ = 8.0 Hz, H-3′), 7.37 (t, 1H, J5′,4′/5′,6′ = 7.2 Hz, H-5′), 7.30 (t, 1H, J4′,3′/4′,5′ = 7.2 Hz, H-4′); EI-MS m/z (% rel. abund.): 313 (M+, 1), 296 (30), 279 (100), 186 (24), 144 (61), 127 (24); HREI-MS m/z: calcd for C16H12N3ClS [M]˙+ [313.0454], found [313.0440]. 1-(3-Chlorophenyl)-3-(quinolin-3-yl)thiourea (3)63 Yield: 70% (219.1 mg); yellow solid; MP: 138–140 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.22 (s, 1H, NHa),10.20 (s, 1H, NHb), 8.94 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.37 (d, 1H, J4,2 = 2.4 Hz, H-4), 7.98 (d, 1H, J5,6 = 8.4 Hz, H-5), 7.95 (d, 1H, J8,7 = 8.0 Hz, H-8), 7.72 (m, 2H, H-6, H-2′), 7.59 (t, 1H, J7,6/7,8 = 8.0 Hz, H-7), 7.45 (d, 1H, J6′,5′ = 8.4 Hz, H-6′), 7.38 (t, 1H, J5′,4′/5′,6′ = 8.0 Hz, H-5′), 7.22 (d, 1H, J4′,5′ = 7.6 Hz, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 180.5, 148.8, 144.8, 140.7, 133.2, 132.6, 130.1, 128.6, 128.5, 128.1, 127.7, 127.6, 126.9, 124.4, 123.2, 122.2; EI-MS m/z (% rel. abund.): 313 (M+, 1), 315 (M+2, 0.6), 279 (96), 186 (100), 169 (40), 144 (48), 127 (47); HREI-MS m/z: calcd for C16H12N3ClS [M]˙+ [313.0451], found [313.0440]. 1-(2,5-Dichlorophenyl)-3-(quinolin-3-yl)thiourea (4) Yield: 71% (246.3 mg); white solid; MP: 180–182 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.36 (s, 1H, NHb), 9.85 (s, 1H, NHa), 8.95 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.44 (br s, 1H, H-4), 7.97 (m, 2H, H-5, H-8), 7.79 (s, 1H, H-6′), 7.70 (t, 1H, J6,5/6,7 = 6.8 Hz, H-6), 7.58 (m, 2H, H-7, H-3′), 7.38 (m, 1H, H-4′); FAB+-MS m/z: 348 (M+ + 1). 1-(4-Nitrophenyl)-3-(quinolin-3-yl)thiourea (5) Yield: 72% (233.2 mg); yellow solid; MP: 162–164 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.64 (s, 1H, NHa), 10.52 (s, 1H, NHb), 8.95 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.42 (br s, 1H, H-4), 8.23 (d, 2H, J3′,2′/5′,6′ = 9.2 Hz, H-3′, H-5′), 7.99 (d, 2H, J5,6/8,7 = 8.4 Hz, H-5, H-8), 7.88 (d, 2H, J6′,5′/2′,3′ = 8.8 Hz, H-2′, H-6′), 7.72 (t, 1H, J6,5/6,7 = 7.2 Hz, H-6), 7.60 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7); FAB+-MS m/z: 325 (M+ + 1); HRFAB+-MS m/z: calcd for C16H13N4SO2 [M + H]+ [325.0716], found [325.0759]. 1-(2-Chloro-4-nitrophenyl)-3-(quinolin-3-yl)thiourea (6) Yield: 75% (268.5 mg); yellow solid; MP: 166–168 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.67 (s, 1H, NHb), 10.06 (s, 1H, NHa), 8.97 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.52 (s, 1H, H-3′), 8.40 (d, 1H, J4,2 = 2.4 Hz, H-4), 8.22 (dd, 1H, J5′,3′ = 2.0 Hz, J5′,6′ = 8.8 Hz, H-5′), 8.17 (d, 1H, J6′,5′ = 9.2 Hz, H-6′), 7.99 (m, 2H, H-5, H-8), 7.72 (t, 1H, J6,5/6,7 = 7.2 Hz, H-6), 7.61 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7); FAB+-MS m/z: 359 (M+ + 1). 1-(Quinolin-3-yl)-3-(3-(trifluoromethyl)phenyl)thiourea (7) Yield: 67% (232.5 mg); white solid; MP: 168–170 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.29 (s, 1H, NHa), 10.28 (s, 1H, NHb), 8.93 (d, 1H, J2,4 = 2.0 Hz, H-2), 8.38 (br. s, 1H, H-4), 7.98 (m, 3H, H-5, H-8, H-5′), 7.79 (d, 1H, J6′,5′ = 7.6 Hz, H-6′), 7.71 (t, 1H, J6,5/6,7 = 7.2 Hz, H-6), 7.58 (m, 2H, H-7, H-2′), 7.49 (d, 1H, J4′,5′ = 7.6 Hz, H-4′); EI-MS m/z (% rel. abund.): 347 (M+, 14), 313 (100), 203 (16), 186 (40), 161 (33), 144 (45); HREI-MS m/z: calcd for C17H12SN3F3 [M]˙+ [347.0705], found [347.0704]. 1-(Quinolin-3-yl)-3-(o-tolyl)thiourea (8) Yield: 75% (219.7 mg); off-white solid; MP: 176–178 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.82 (s, 1H, NHa), 9.36 (s, 1H, NHb), 8.91 (dd, 1H, J2,4 = 1.6 Hz, J2,3 = 4.0 Hz, H-2), 8.33 (d, 1H, J4,3 = 8.0 Hz, H-4), 7.94 (d, 1H, J6′,5′ = 8.4 Hz, H-6′), 7.75 (t, 1H, J5′,4′/5′,6′ = 7.2 Hz, H-5′), 7.59 (m, 2H, H-5, H-8), 7.24 (m, 2H, H-6, H-7), 7.18 (m, 2H, H-3′, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 182.1, 150.5, 148.3, 137.8, 135.5, 135.1, 131.8, 130.3, 129.0, 128.2, 127.8, 126.7, 126.1, 125.7, 125.5, 121.3, 17.8; EI-MS m/z (% rel. abund.): 293 (M+, 5), 259 (56), 186 (100), 144 (64), 128 (79), 106 (80); HREI-MS m/z: calcd for C17H15N3S [M]˙+ [293.0985], found [293.0987]. 1-(2-Methoxyphenyl)-3-(quinolin-3-yl)thiourea (9) Yield: 76% (234.8 mg); yellow solid; MP: 194–196 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.14 (s, 1H, NHb), 9.50 (s, 1H, NHa), 8.93 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.46 (br s, 1H, H-4), 7.97 (d, 1H, J5,6 = 8.4 Hz, H-5), 7.93 (d, 1H, J8,7 = 7.6 Hz, H-8), 7.84 (d, 1H, J6′,5′ = 6.0 Hz, H-6′), 7.68 (t, 1H, J6,5/6,7 = 6.8 Hz, H-6), 7.58 (t, 1H, J7,6/7,8 = 6.8 Hz, H-7), 7.19 (t, 1H, J4′,3′/4′,5′ = 7.2 Hz, H-4′), 7.09 (d, 1H, J3′,4′ = 7.2 Hz, H-3′), 6.95 (t, 1H, J5′,4′/5′,6′ = 7.6 Hz, H-5′); EI-MS m/z (% rel. abund.): 309 (M+, 2), 275 (100), 260 (38), 186 (87), 144 (29), 128 (51); HREI-MS m/z: calcd for C17H15N3SO [M]˙+ [309.0927], found [309.0936]. 1-(4-Methoxyphenyl)-3-(quinolin-3-yl)thiourea (10)63 Yield: 79% (244.1 mg); white solid; MP: 202–204 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.02 (s, 1H, NHa), 9.92 (s, 1H, NHb), 8.93 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.35 (d, 1H, J4,2 = 1.6 Hz, H-4), 7.97 (d, 1H, J5,6 = 8.4 Hz, H-5), 7.92 (d, 1H, J8,7 = 8.0 Hz, H-8), 7.68 (t, 1H, J6,7/6,5 = 6.8 Hz, H-6), 7.58 (t, 1H, J7,6/7,8 = 8.0 Hz, H-7), 7.36 (d, 2H, J2′,3′/6′,5′ = 8.8 Hz, H-2′, H-6′), 6.94 (d, 2H, J3′,2′/5′,6′ = 9.2 Hz, H-3′, H-5′); EI-MS m/z (% rel. abund.): 309 (M+, 2), 275 (88), 260 (65), 186 (100), 165 (57), 144 (64), 128 (83); HREI-MS m/z: calcd for C17H15N3SO [M]˙+ [309.0932], found [309.0936]. 1-(4-Ethoxyphenyl)-3-(quinolin-3-yl)thiourea (11) Yield: 74% (239.0 mg); off-white solid; MP: 215–217 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.91 (s, 1H, NHa), 9.88 (s, 1H, NHb), 8.93 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.35 (d, 1H, J4,2 = 1.6 Hz, H-4), 7.96 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.92 (d, 1H, J8,7 = 7.6 Hz, H-8), 7.68 (t, 1H, J6,7/6,5 = 7.2 Hz, H-6), 7.57 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.35 (d, 2H, J2′,3′/6′,5′ = 8.8 Hz, H-2′, H-6′), 6.92 (d, 2H, J3′,2′/5′,6′ = 8.8 Hz, H-3′, H-5′); 13C-NMR (100 MHz, DMSO-d6): δC 180.6, 156.0, 148.9, 144.6, 133.6, 131.6, 128.5, 128.4, 127.8, 127.6, 127.5, 126.7, 126.1, 114.3, 63.1, 14.6; EI-MS m/z (% rel. abund.): 323 (M+, 3), 289 (33), 260 (21), 186 (100), 137 (62), 128 (68), 108 (80); HREI-MS m/z: calcd for C18H17N3SO [M]˙+ [323.1107], found [323.1092]. 1-Cyclohexyl-3-(quinolin-3-yl)thiourea (12) Yield: 61% (173.8 mg); yellow solid; MP: 212–214 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.62 (s, 1H, NHa), 8.86 (d, 1H, J2,4 = 1.6 Hz, H-2), 8.44 (s, 1H, NHb), 7.95 (m, 2H, H-4, H-5), 7.90 (d, 1H, J8,7 = 8.0 Hz, H-8), 7.66 (t, 1H, J6,7/6,5 = 7.2 Hz, H-6), 7.56 (t, 1H, J7,6/7,8 = 7.2 Hz, H-7); 13C-NMR (100 MHz, DMSO-d6): δC 179.9, 148.1, 144.4, 133.6, 128.4, 128.1, 127.6, 127.5, 126.8, 126.1, 52.3, 31.8, 25.1, 24.5; EI-MS m/z (% rel. abund.): 285 (M+, 6), 251 (14), 186 (35), 169 (100), 144 (31), 128 (20); HREI-MS m/z: calcd for C16H19N3S [M]˙+ [285.1302], found [285.1300]. 1-Phenyl-3-(quinolin-5-yl)thiourea (13)60 Yield: 75% (209.2 mg); brown solid; MP: 176–178 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.91 (s, 1H, NHa), 9.87 (s, 1H, NHb), 8.91 (dd, 1H, J2,4 = 1.6 Hz, J2,3 = 4.4 Hz, H-2), 8.35 (d, 1H, J4,3 = 8.4 Hz, H-4), 7.93 (d, 1H, J8,7 = 8.4 Hz, H-8), 7.75 (t, 1H, J7,6/7,8 = 8.0 Hz, H-7), 7.58 (m, 2H, H-3, H-6), 7.51 (d, 2H, J2′,3′/6′,5′ = 7.6 Hz, H-2′, H-6′), 7.33 (t, 2H, J3′,2′/5′,6′ = 7.6 Hz, H-3′, H-5′), 7.13 (t, 1H, J4′,3′/4′,5′ = 7.2 Hz, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 181.5, 150.5, 148.3, 139.4, 135.6, 131.9, 129.0, 128.4, 127.6, 125.4, 125.3, 124.7, 124.1, 121.3; EI-MS m/z (% rel. abund.): 279 (M+, 10), 245 (100), 186 (94), 144 (39), 128 (54), 93 (51); HREI-MS m/z: calcd for C16H13SN3 [M]˙+ [279.0802], found [279.0830]. 1-(2-Fluorophenyl)-3-(quinolin-5-yl)thiourea (14) Yield: 77% (228.7 mg); brown solid; MP: 171–173 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.07 (s, 1H, NHb), 9.54 (s, 1H, NHa), 8.92 (dd, 1H, J2,4 = 1.2 Hz, J2,3 = 4.0 Hz, H-2), 8.34 (d, 1H, J4,3 = 8.4 Hz, H-4), 7.96 (d, 1H, J6′,5′ = 8.8 Hz, H-6′), 7.76 (t, 1H, J3,2/3,4 = 8.4 Hz, H-3), 7.59 (m, 3H, H-6, H-7, H-8), 7.24 (m, 2H, H-3′, H-5′), 7.17 (m, 1H, H-4′); EI-MS m/z (% rel. abund.): 297 (M+, 16), 263 (100), 186 (87), 144 (49), 128 (62), 111 (46); HREI-MS m/z: calcd for C16H12N3FS [M]˙+ [297.0735], found [297.0736]. 1-(3-Chlorophenyl)-3-(quinolin-5-yl)thiourea (15) Yield: 75% (234.7 mg); off-white solid; MP: 145–147 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.08 (s, 1H, NHa), 9.98 (s, 1H, NHb), 8.92 (d, 1H, J2,4 = 3.2 Hz, H-2), 8.34 (d, 1H, J4,3 = 8.4 Hz, H-4), 7.95 (d, 1H, J6,7 = 7.6 Hz, H-6), 7.76 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.72 (s, 1H, H-2′), 7.57 (m, 2H, H-3, H-8), 7.44 (m, 1H, H-6′), 7.34 (t, 1H, J5′,4′/5′,6′ = 8.0 Hz, H-5′), 7.17 (d, 1H, J4′,5′ = 8.0 Hz, H-4′); EI-MS m/z (% rel. abund.): 313 (M+, 6), 315 (M+2, 2), 279 (100), 186 (86), 169 (27), 144 (37), 128 (55); HREI-MS m/z: calcd for C16H12N3ClS [M]˙+ [313.0429], found [313.0440]. 1-(2,5-Dichlorophenyl)-3-(quinolin-5-yl)thiourea (16) Yield: 76% (263.7 mg); brown solid; MP: 185–187 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.23 (s, 1H, NHb), 9.58 (s, 1H, NHa), 8.92 (dd, 1H, J2,4 = 1.6 Hz, J2,3 = 4.0 Hz, H-2), 8.37 (d, 1H, J4,3 = 8.4 Hz, H-4), 7.95 (d, 1H, J6,7 = 8.4 Hz, H-6), 7.79 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.76 (s, 1H, H-6′), 7.61 (m, 2H, H-3, H-8), 7.54 (d, 1H, J3′,4′ = 8.8 Hz, H-3′), 7.33 (dd, 1H, J4′,6′ = 2.4 Hz, J4′,3′ = 8.8 Hz, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 182.1, 151.8, 150.6, 148.3, 137.8, 134.9, 131.8, 131.0, 130.7, 129.3, 129.0, 128.1, 127.4, 125.7, 125.3, 121.4; FAB+-MS m/z: 348 (M+ + 1). 1-(4-Nitrophenyl)-3-(quinolin-5-yl)thiourea (17) Yield: 74% (239.7 mg); brown solid; MP: 177–179 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.49 (s, 1H, NHa), 10.36 (s, 1H, NHb), 8.93 (d, 1H, J2,4 = 2.8 Hz, H-2), 8.36 (d, 1H, J4,3 = 8.4 Hz, H-4), 8.21 (d, 2H, J3′,2′/5′,6′ = 9.2 Hz, H-3′, H-5′), 7.98 (d, 1H, J6,7 = 8.4 Hz, H-6), 7.91 (d, 2H, J2′,3′/6′,5′ = 9.2 Hz, H-2′, H-6′), 7.79 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.59 (m, 2H, H-3, H-8); 13C-NMR (100 MHz, DMSO-d6): δC 181.3, 150.6, 148.3, 146.2, 142.5, 131.8, 129.1, 128.0, 126.4, 125.4, 125.1, 124.3, 122.0, 121.4, 112.3; FAB+-MS m/z: 325 (M+ + 1); HRFAB+-MS m/z: calcd for C16H13N4SO2 [M + H]+ [325.0747], found [325.0759]. 1-(2-Chloro-4-nitrophenyl)-3-(quinolin-5-yl)thiourea (18) Yield: 78% (279.2 mg); white solid; MP: 182–184 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.55 (s, 1H, NHb), 9.85 (s, 1H, NHa), 8.94 (dd, 1H, J2,4 = 1.6 Hz, J2,3 = 4.0 Hz, H-2), 8.38 (m, 2H, H-4, H-3′), 8.19 (m, 2H, H-5′, H-6′), 7.99 (d, 1H, J6,7 = 8.4 Hz, H-6), 7.80 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.67 (d, 1H, J8,7 = 6.8 Hz, H-8), 7.62 (t, 1H, J3,2/3,4 = 4.0 Hz, H-3); FAB+-MS m/z: 359 (M+ + 1). 1-(Quinolin-5-yl)-3-(3-(trifluoromethyl)phenyl)thiourea (19) Yield: 69% (239.4 mg); off-white solid; MP: 174–176 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.17 (s, 1H, NHa), 10.04 (s, 1H, NHb), 8.92 (d, 1H, J2,4 = 2.8 Hz, H-2), 8.36 (d, 1H, J4,3 = 8.4 Hz, H-4), 7.97 (m, 2H, H-6, H-2′), 7.78 (m, 2H, H-3, H-7), 7.57 (m, 3H, H-4′, H-5′, H-6′), 7.46 (d, 1H, J8,7 = 8.0 Hz, H-8); EI-MS m/z (% rel. abund.): 347 (M+, 2), 313 (48), 203 (27), 186 (100), 161 (54), 144 (30); HREI-MS m/z: calcd for C17H12SN3F3 [M]˙+ [347.0696], found [347.0704]. 1-(Quinolin-5-yl)-3-(o-tolyl)thiourea (20) Yield: 79% (231.4 mg); brown solid; MP: 184–186 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.02 (s, 1H, NHa), 9.97 (s, 1H, NHb), 8.93 (d, 1H, J2,4 = 2.4 Hz, H-2), 8.36 (d, 1H, J4,2 = 1.6 Hz, H-4), 7.97 (d, 1H, J6,7 = 8.0 Hz, H-6), 7.92 (d, 1H, J6′,5′ = 8.0 Hz, H-6′), 7.68 (t, 1H, J7,6/7,8 = 7.2 Hz, H-7), 7.57 (t, 1H, J5′,4′/5′,6′ = 7.2 Hz, H-5′), 7.37 (d, 2H, J3,4/8,7 = 8.0 Hz, H-3, H-8), 7.17 (d, 2H, J3′,4′/4′,3′ = 8.4 Hz, H-3′, H-4′); EI-MS m/z (% rel. abund.): 293 (M+, 3), 259 (100), 186 (63), 144 (33), 128 (28), 106 (33); HREI-MS m/z: calcd for C17H15N3S [M]˙+ [293.0977], found [293.0987]. 1-(2-Methoxyphenyl)-3-(quinolin-5-yl)thiourea (21) Yield: 78% (241.0 mg); off-white solid; MP: 211–213 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.89 (s, 1H, NHb), 9.35 (s, 1H, NHa), 8.91 (d, 1H, J2,4 = 2.8 Hz, H-2), 8.36 (d, 1H, J4,3 = 8.0 Hz, H-4), 7.94 (d, 1H, J6,7 = 8.0 Hz, H-6), 7.81 (d, 1H, J6′,5′ = 7.2 Hz, H-6′), 7.75 (t, 1H, J7,6/7,8 = 8.0 Hz, H-7), 7.58 (m, 2H, H-3, H-8), 7.18 (t, 1H, J4′,3′/4′,5′ = 7.6 Hz, H-4′), 7.06 (d, 1H, J3′,4′ = 8.0 Hz, H-3′), 6.93 (t, 1H, J5′,4′/5′,6′ = 7.6 Hz, H-5′); EI-MS m/z (% rel. abund.): 309 (M+, 1), 275 (20), 260 (6), 186 (100), 144 (11), 128 (46); HREI-MS m/z: calcd for C17H15N3SO [M]˙+ [309.0927], found [309.0936]. 1-(4-Methoxyphenyl)-3-(quinolin-5-yl)thiourea (22) Yield: 82% (253.3 mg); off-white solid; MP: 205–207 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.75 (s, 1H, NHa), 9.66 (s, 1H, NHb), 8.90 (d, 1H, J2,4 = 2.8 Hz, H-2), 8.33 (d, 1H, J4,3 = 8.8 Hz, H-4), 7.93 (d, 1H, J6,7 = 8.0 Hz, H-6), 7.74 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.56 (m, 2H, H-3, H-8), 7.37 (m, 2H, H-2′, H-6′), 6.90 (d, 2H, J3′,2′/5′,6′ = 8.8 Hz, H-3′, H-5′); EI-MS m/z (% rel. abund.): 309 (M+, 1), 275 (33), 260 (24), 186 (100), 165 (16), 144 (23), 128 (58); HREI-MS m/z: calcd for C17H15N3SO [M]˙+ [309.0932], found [309.0936]. 1-(4-Ethoxyphenyl)-3-(quinolin-5-yl)thiourea (23) Yield: 75% (242.2 mg); brown solid; MP: 206–208 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.74 (s, 1H, NHa), 9.65 (s, 1H, NHb), 8.90 (d, 1H, J2,4 = 2.8 Hz, H-2), 8.33 (d, 1H, J4,3 = 8.4 Hz, H-4), 7.93 (d, 1H, J6,7 = 8.0 Hz, H-6), 7.74 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.56 (m, 2H, H-3, H-8), 7.33 (d, 2H, J2′,3′/6′,5′ = 8.8 Hz, H-2′, H-6′), 6.88 (d, 2H, J3′,2′/5′,6′ = 9.2 Hz, H-3′, H-5′); 13C-NMR (100 MHz, DMSO-d6): δC 181.6, 156.0, 150.4, 148.3, 131.9, 129.0, 127.5, 127.3, 126.3, 125.5, 125.4, 121.2, 115.5, 114.1, 63.1, 14.6; EI-MS m/z (% rel. abund.): 323 (M+, 4), 289 (50), 260 (44), 186 (100), 137 (30), 128 (62), 108 (44); HREI-MS m/z: calcd for C18H17N3SO [M]˙+ [323.1099], found [323.1092]. 1-(Naphthalen-2-yl)-3-(quinolin-5-yl)thiourea (24) Yield: 67% (220.4 mg); brown solid; MP: 222–224 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.95 (s, 1H, NHa), 9.82 (s, 1H, NHb), 8.90 (d, 1H, J2,4 = 2.8 Hz, H-2), 8.37 (d, 1H, J4,3 = 8.4 Hz, H-4), 8.03 (d, 1H, J6,7 = 8.4 Hz, H-6), 7.95 (m, 2H, H-5′, H-7), 7.86 (d, 1H, J8′,7′ = 8.0 Hz, H-8′), 7.75 (t, 1H, J7′,6′/7′,8′ = 7.6 Hz, H-7′), 7.58 (m, 6H, H-3, H-8, H-1′, H-3′, H-4′, H-6′); EI-MS m/z (% rel. abund.): 329 (M+, 2), 295 (61), 186 (96), 143 (100), 128 (51), 115 (32); HREI-MS m/z: calcd for C20H15N3S [M]˙+ [329.0992], found [329.0987]. 1-Cyclohexyl-3-(quinolin-5-yl)thiourea (25) Yield: 64% (182.4 mg); off-white solid; MP: 225–227 °C; 1H-NMR (400 MHz, DMSO-d6): δH 9.48 (s, 1H, NHa), 8.90 (dd, 1H, J2,4 = 1.6 Hz, J2,3 = 4.0 Hz, H-7), 8.23 (d, 1H, J4,3 = 8.4 Hz, H-4), 7.91 (d, 1H, J6,7 = 8.4 Hz, H-6), 7.73 (t, 1H, J7,6/7,8 = 7.6 Hz, H-7), 7.65 (s, 1H, NHb), 7.55 (m, 2H, H-3, H-8); EI-MS m/z (% rel. abund.): 285 (M+, 24), 251 (13), 186 (91), 169 (100), 144 (96), 128 (37); HREI-MS m/z: calcd for C16H19N3S [M]˙+ [285.1297], found [285.1300]. 1-Phenyl-3-(quinolin-8-yl)thiourea (26)61 Yield: 82% (228.7 mg); yellow solid; MP: 172–174 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.74 (s, 1H, NHa), 10.61 (s, 1H, NHb), 9.24 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.89 (dd, 1H, J4,2 = 1.6 Hz, J4,3 = 4.0 Hz, H-4), 8.44 (dd, 1H, J7,5 = 1.6 Hz, J7,6 = 8.4 Hz, H-7), 7.64 (m, 5H, H-3, H-5, H-6, H-2′, H-6′), 7.41 (t, 2H, J3′,2′/3′,4′/5′,4′/5′,6′ = 7.6 Hz, H-3′, H-5′), 7.22 (t, 1H, J4′,3′/4′,5′ = 7.2 Hz, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 177.9, 148.7, 138.9, 138.7, 136.7, 135.1, 128.7, 127.8, 126.3, 125.0, 124.0, 122.1, 122.0, 118.1; EI-MS m/z (% rel. abund.): 279 (M+, 2), 244 (100), 186 (23), 144 (14), 128 (12), 93 (22); HREI-MS m/z: calcd for C16H13SN3 [M]˙+ [279.0823], found [279.0830]. 1-(2-Fluorophenyl)-3-(quinolin-8-yl)thiourea (27)62 Yield: 80% (237.6 mg); green solid; MP: 172–174 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.73 (s, 1H, NHb), 10.52 (s, 1H, NHa), 9.22 (d, 1H, J2,3 = 7.2 Hz, H-2), 8.90 (dd, 1H, J4,2 = 1.6 Hz, J4,3 = 4.4 Hz, H-4), 8.43 (dd, 1H, J6′,4′ = 1.2 Hz, J6′,5′ = 8.4 Hz, H-6′), 7.67 (m, 3H, H-5, H-6, H-7), 7.60 (t, 1H, J3,2/3,4 = 8.0 Hz, H-3), 7.31 (m, 2H, H-3′, H-5′), 7.23 (m, 1H, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 179.4, 157.5, 155.6, 148.7, 138.9, 136.7, 135.1, 129.2, 127.8, 127.7, 126.4, 126.3, 124.3, 122.2, 118.2, 116.0, 115.8; EI-MS m/z (% rel. abund.): 297 (M+, 1), 277 (83), 263 (56), 187 (77), 153 (98), 144 (100); HREI-MS m/z: calcd for C16H12N3FS [M]˙+ [297.0728], found [297.0736]. 1-(2-Chlorophenyl)-3-(quinolin-8-yl)thiourea (28)62 Yield: 77% (241.0 mg); brown solid; MP: 142–144 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.76 (s, 1H, NHb), 10.55 (s, 1H, NHa), 9.25 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.91 (d, 1H, J4,2 = 2.8 Hz, H-4), 8.44 (d, 1H, J7,6 = 8.4 Hz, H-7), 7.71 (d, 1H, J6′,5′ = 8.0 Hz, H-6′), 7.64 (m, 2H, H-5, H-3′), 7.59 (t, 2H, J3,2/3,4/6,5/6,7 = 8.4 Hz, H-3, H-6), 7.41 (t, 1H, J5′,4′/5′,6′ = 7.2 Hz, H-5′), 7.33 (t, 1H, J4′,3′/4′,5′ = 7.6 Hz, H-4′); 13C-NMR (100 MHz, DMSO-d6): δC 179.4, 148.7, 138.9, 136.7, 135.9, 135.2, 130.5, 129.6, 128.0, 127.8, 127.3, 126.3, 122.1, 118.1; FAB+-MS m/z: 314 (M+1); HRFAB+-MS m/z: calcd for C16H13N3ClS [M + H]+ [314.0537], found [314.0519]. 1-(3-Chlorophenyl)-3-(quinolin-8-yl)thiourea (29)62 Yield: 81% (253.5 mg); brown solid; MP: 141–143 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.89 (s, 1H, NHa), 10.68 (s, 1H, NHb), 9.17 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.93 (d, 1H, J4,2 = 2.8 Hz, H-4), 8.44 (d, 1H, J7,6 = 7.2 Hz, H-7), 7.90 (s, 1H, H-2′), 7.72 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.66 (t, 1H, J3,2/3,4 = 4.4 Hz, H-3), 7.61 (t, 1H, J6,5/6,7 = 8.0 Hz, H-6), 7.50 (d, 1H, J6′,5′ = 8.0 Hz, H-6′), 7.41 (t, 1H, J5′,4′/5′,6′ = 8.4 Hz, H-5′), 7.24 (d, 1H, J4′,5′ = 7.6 Hz, H-4′); EI-MS m/z (% rel. abund.): 313 (M+, 1), 278 (100), 244 (92), 186 (14), 169 (19), 144 (53); HREI-MS m/z: calcd for C16H12N3ClS [M]˙+ [313.0445], found [313.0440]. 1-(3-Bromophenyl)-3-(quinolin-8-yl)thiourea (30) Yield: 79% (282.0 mg); off-white solid; MP: 152–154 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.88 (s, 1H, NHa), 10.67 (s, 1H, NHb), 9.16 (d, 1H, J2,3 = 6.4 Hz, H-2), 8.92 (br s, 1H, H-4), 8.44 (d, 1H, J7,6 = 7.6 Hz, H-7), 8.01 (s, 1H, H-2′), 7.63 (m, 4H, H-3, H-5, H-6, H-4′), 7.36 (m, 2H, H-5′, H-6′); 13C-NMR (100 MHz, DMSO-d6): δC 177.8, 148.8, 140.6, 139.1, 136.8, 134.9, 130.5, 127.8, 127.3, 126.3, 125.9, 122.4, 122.2, 121.0, 118.5; EI-MS m/z (% rel. abund.): 357 (M+, 2), 359 (M+2, 2), 324 (70), 244 (100), 215 (42), 186 (49), 144 (67); HREI-MS m/z: calcd for C16H12N3BrS [M]˙+ [356.9939], found [356.9935]. 1-(2,4-Difluorophenyl)-3-(quinolin-8-yl)thiourea (31) Yield: 75% (236.2 mg); brown solid; MP: 178–180 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.73 (s, 1H, NHb), 10.47 (s, 1H, NHa), 9.20 (d, 1H, J2,3 = 7.2 Hz, H-2), 8.92 (dd, 1H, J4,2 = 2.8 Hz, J4,3 = 4.0 Hz, H-4), 8.44 (dd, 1H, J7,5 = 1.2 Hz, J7,6 = 8.0 Hz, H-7), 7.71 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.64 (m, 3H, H-3, H-6, H-3′), 7.37 (t, 1H, J6′,5′ = 8.0 Hz, H-6′), 7.14 (t, 1H, J5′,6′ = 8.8 Hz, H-5′); 13C-NMR (100 MHz, DMSO-d6): δC 179.8, 148.8, 138.9, 136.8, 135.1, 130.7, 127.8, 126.3, 122.3, 122.2, 118.2, 111.2, 111.1, 104.4, 104.1; EI-MS m/z (% rel. abund.): 315 (M+, 1), 295 (36), 281 (100), 262 (84), 187 (39), 171 (29), 144 (42); HREI-MS m/z: calcd for C16H11N3F2S [M]˙+ [315.0648], found [315.0642]. 1-(2,5-Dichlorophenyl)-3-(quinolin-8-yl)thiourea (32) Yield: 80% (277.6 mg); brown solid; MP: 179–181 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.89 (s, 1H, NHb), 10.63 (s, 1H, NHa), 9.18 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.95 (dd, 1H, J4,2 = 1.2 Hz, J4,3 = 4.0 Hz, H-4), 8.45 (d, 1H, J7,6 = 7.6 Hz, H-7), 7.82 (d, 1H, J6′,4′ = 2.4 Hz, H-6′), 7.73 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.67 (t, 1H, J3,2/3,4 = 4.4 Hz, H-3), 7.61 (m, 2H, H-6, H-3′), 7.39 (d, 1H, J4′,3′ = 8.4 Hz, H-4′); FAB+-MS m/z: 348 (M+ + 1). 1-(4-Nitrophenyl)-3-(quinolin-8-yl)thiourea (33) Yield: 82% (265.6 mg); yellow solid; MP: 184–186 °C; 1H-NMR (400 MHz, DMSO-d6): δH 11.33 (s, 1H, NHa), 10.87 (s, 1H, NHb), 9.14 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.96 (dd, 1H, J4,2 = 2.4 Hz, J4,3 = 4.0 Hz, H-4), 8.46 (d, 1H, J7,6 = 8.0 Hz, H-7), 8.25 (d, 2H, J3′,2′/5′,6′ = 9.2 Hz, H-3′, H-5′), 8.05 (d, 2H, J2′,3′/6′,5′ = 8.8 Hz, H-2′, H-6′), 7.77 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.68 (t, 1H, J3,2/3,4 = 4.0 Hz, H-3), 7.63 (t, 1H, J6,5/6,7 = 8.0 Hz, H-6); EI-MS m/z (% rel. abund.): 324 (M+, 1), 290 (77), 243 (68), 186 (71), 180 (55), 144 (100); HREI-MS m/z: calcd for C16H12N4SO2 [M]˙+ [324.0677], found [324.0681]. 1-(2-Chloro-4-nitrophenyl)-3-(quinolin-8-yl)thiourea (34) Yield: 81% (289.9 mg); green solid; MP: 187–189 °C; 1H-NMR (400 MHz, DMSO-d6): δH 11.16 (s, 1H, NHb), 10.83 (s, 1H, NHa), 9.11 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.98 (d, 1H, J4,2 = 2.8 Hz, H-4), 8.46 (d, 1H, J5′,6′ = 7.6 Hz, H-5′), 8.40 (s, 1H, H-3′), 8.21 (m, 2H, H-7, H-6′), 7.77 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.67 (t, 1H, J3,2/3,4 = 4.4 Hz, H-3), 7.63 (t, 1H, J6,5/6,7 = 8.0 Hz, H-6); 13C-NMR (100 MHz, DMSO-d6): δC 178.9, 149.1, 144.4, 142.4, 139.4, 136.8, 134.8, 129.1, 128.6, 127.9, 126.2, 124.8, 123.2, 122.2, 122.1, 119.7; EI-MS m/z (% rel. abund.): 358 (M+, 1), 360 (M+2, 5), 346 (3), 345 (6), 343 (4), 333 (4), 318 (2); HREI-MS m/z: calcd for C16H11N4SO2Cl [M]˙+ [358.0276], found [358.0291]. 1-(Quinolin-8-yl)-3-(3-(trifluoromethyl)phenyl)thiourea (35)62 Yield: 72% (249.8 mg); brown solid; MP: 180–182 °C; 1H-NMR (400 MHz, DMSO-d6): δH 11.02 (s, 1H, NHa), 10.71 (s, 1H, NHb), 9.16 (d, 1H, J2,3 = 6.8 Hz, H-2), 8.94 (dd, 1H, J4,2 = 1.6 Hz, J4,3 = 4.0 Hz, H-4), 8.45 (dd, 1H, J7,5 = 1.6 Hz, J7,6 = 8.4 Hz, H-7), 8.16 (s, 1H, H-2′), 7.87 (d, 1H, J4′,5′ = 8.0 Hz, H-4′), 7.73 (d, 1H, J5,6 = 7.6 Hz, H-5), 7.67 (m, 1H, H-3), 7.62 (t, 2H, J6,5/6,7/5′,4′/5′,6′ = 8.0 Hz, H-6, H-5′), 7.52 (d, 1H, J6′,5′ = 7.6 Hz, H-6′); 13C-NMR (100 MHz, DMSO-d6): δC 178.0, 148.8, 139.9, 139.1, 136.8, 134.9, 129.7, 127.9, 127.2, 126.3, 122.5, 122.2, 121.0, 119.7, 118.6; EI-MS m/z (% rel. abund.): 347 (M+, 8), 312 (100), 244 (33), 203 (41), 186 (28), 144 (38); HREI-MS m/z: calcd for C17H12SN3F3 [M]˙+ [347.0709], found [347.0704]. 1-(Quinolin-8-yl)-3-(o-tolyl)thiourea (36) Yield: 80% (234.4 mg); brown solid; MP: 189–191 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.47 (s, 1H, NHa), 10.30 (s, 1H, NHb), 9.15 (d, 1H, J2,3 = 7.2 Hz, H-2), 8.80 (br s, 1H, H-4), 8.41 (d, 1H, J7,6 = 7.6 Hz, H-7), 7.67 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.61 (m, 2H, H-3, H-6), 7.32 (m, 2H, H-3′, H-5′), 7.27 (m, 2H, H-4′, H-6′); EI-MS m/z (% rel. abund.): 293 (M+, 5), 258 (100), 187 (16), 144 (30), 129 (25), 117 (10); HREI-MS m/z: calcd for C17H15N3S [M]˙+ [293.0977], found [293.0987]. 1-(2-Methoxyphenyl)-3-(quinolin-8-yl)thiourea (37)62 Yield: 79% (244.1 mg); brown solid; MP: 165–167 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.59 (s, 1H, NHb), 10.16 (s, 1H, NHa), 9.23 (d, 1H, J2,3 = 7.2 Hz, H-2), 8.83 (d, 1H, J4,2 = 2.8 Hz, H-4), 8.40 (dd, 1H, J7,5 = 1.2 Hz, J7,6 = 8.0 Hz, H-7), 7.67 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.61 (m, 3H, H-3, H-6, H-6′), 7.28 (t, 1H, J4′,3′/4′,5′ = 6.8 Hz, H-4′), 7.16 (d, 1H, J3′,4′ = 6.8 Hz, H-3′), 6.99 (t, 1H, J5′,4′/5′,6′ = 7.2 Hz, H-5′); 13C-NMR (100 MHz, DMSO-d6): δC 178.5, 153.3, 148.6, 139.0, 136.7, 135.3, 127.8, 127.7, 127.3, 126.6, 126.3, 122.0, 121.9, 120.1, 118.1, 111.9, 55.6; EI-MS m/z (% rel. abund.): 309 (M+, 2), 275 (95), 258 (39), 244 (67), 186 (100), 165 (99), 144 (91); HREI-MS m/z: calcd for C17H15N3SO [M]˙+ [309.0945], found [309.0936]. 1-(4-Methoxyphenyl)-3-(quinolin-8-yl)thiourea (38)62 Yield: 85% (262.6 mg); brown solid; MP: 187–189 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.53 (s, 1H, NHa), 10.50 (s, 1H, NHb), 9.25 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.85 (d, 1H, J4,2 = 2.4 Hz, H-4), 8.41 (dd, 1H, J7,5 = 1.2 Hz, J7,6 = 8.0 Hz, H-7), 7.67 (d, 1H, J5,6 = 7.6 Hz, H-5), 7.61 (m, 2H, H-3, H-6), 7.42 (d, 2H, J2′,3′/6′,5′ = 8.8 Hz, H-2′, H-6′), 6.98 (d, 2H, J3′,2′/5′,6′ = 9.2 Hz, H-3′, H-5′); 13C-NMR (100 MHz, DMSO-d6): δC 178.1, 157.0, 148.6, 138.8, 136.7, 135.2, 131.2, 127.7, 126.3, 122.1, 121.7, 117.6, 114.0, 55.3; EI-MS m/z (% rel. abund.): 309 (M+, 3), 275 (96), 260 (100), 186 (46), 165 (51), 144 (64), 128 (15); HREI-MS m/z: calcd for C17H15N3SO [M]˙+ [309.0937], found [309.0936]. 1-(4-Ethoxyphenyl)-3-(quinolin-8-yl)thiourea (39) Yield: 79% (255.1 mg); brown solid; MP: 189–191 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.52 (s, 1H, NHa), 10.50 (s, 1H, NHb), 9.26 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.85 (d, 1H, J4,2 = 2.8 Hz, H-4), 8.40 (dd, 1H, J7,5 = 1.2 Hz, J7,6 = 7.2 Hz, H-7), 7.62 (m, 3H, H-3, H-5, H-6), 7.41 (d, 2H, J2′,3′/6′,5′ = 8.8 Hz, H-2′, H-6′), 6.96 (d, 2H, J3′,2′/5′,6′ = 8.8 Hz, H-3′, H-5′); EI-MS m/z (% rel. abund.): 323 (M+, 4), 289 (61), 260 (89), 186 (45), 179 (54), 151 (71), 144 (100); HREI-MS m/z: calcd for C18H17N3SO [M]˙+ [323.1087], found [323.1092]. 1-(Naphthalen-2-yl)-3-(quinolin-8-yl)thiourea (40) Yield: 71% (233.5 mg); brown solid; MP: 209–211 °C; 1H-NMR (400 MHz, DMSO-d6): δH 10.77 (s, 1H, NHa), 10.67 (s, 1H, NHb), 9.33 (d, 1H, J2,3 = 7.6 Hz, H-2), 8.74 (br s, 1H, H-4), 8.40 (d, 1H, J7,6 = 7.2 Hz, H-7), 8.01 (m, 2H, H-5′, H-8′), 7.94 (d, 1H, J3′,4′ = 8.0 Hz, H-3′), 7.67 (d, 1H, J5,6 = 8.0 Hz, H-5), 7.58 (m, 6H, H-3, H-6, H-1′, H-4′, H-6′, H-7′); 13C-NMR (100 MHz, DMSO-d6): δC 179.7, 148.5, 138.7, 136.7, 135.2, 134.3, 134.0, 130.0, 128.2, 127.7, 127.2, 126.4, 126.3, 125.8, 125.7, 122.9, 122.1, 121.9, 117.5; EI-MS m/z (% rel. abund.): 329 (M+, 1), 294 (48), 185 (100), 144 (55), 127 (28), 117 (21); HREI-MS m/z: calcd for C20H15N3S [M]˙+ [329.0986], found [329.0987]. (E)-1-(4-((4-(Dimethylamino)phenyl)diazenyl)phenyl)-3-(quinolin-8-yl)thiourea (41) Yield: 85% (362.1 mg); brown solid; MP: 207–209 °C; 1H-NMR (400 MHz, DMSO-d6): δH 11.00 (s, 1H, NHa), 10.71 (s, 1H, NHb), 9.21 (d, 1H, J2,3 = 8.0 Hz, H-2), 8.92 (d, 1H, J4,2 = 3.2 Hz, H-4), 8.44 (d, 1H, J7,6 = 7.6 Hz, H-7), 7.80 (m, 6H, H-2′, H-3′, H-5′, H-6′, H-2′′, H-6′′), 7.72 (d, 1H, J5,6 = 7.2 Hz, H-5), 7.63 (m, 2H, H-3, H-6), 6.84 (d, 2H, J3′′,2′′/5′′,6′′ = 9.2 Hz, H-3′′, H-5′′); 13C-NMR (100 MHz, DMSO-d6): δC 177.5, 152.3, 149.0, 148.8, 142.6, 140.3, 136.8, 135.0, 127.8, 126.3, 124.5, 123.5, 122.3, 122.2, 118.4, 111.6; ESI+-MS m/z: 427 (M+ + 1); HRESI+-MS m/z: calcd for C24H23N6S [M + H]+ [427.1714], found [427.1699]. Enzyme inhibition assays In vitro α-amylase inhibitory activity The α-amylase inhibitory activity was determined by the methods described earlier.71,72 A volume of 500 µL of test sample (10–1000 µM) and 500 µL of substrate α-amylase solution (0.5 mg mL−1) in 0.2 mM phosphate buffer (pH 6.9) were incubated at 25 °C for 10 min. After pre-incubation, 500 µL of 1% starch solution in 0.02 M sodium phosphate buffer (pH 6.9) was added and incubated at 25 °C for 10 minutes. The reaction was stopped by adding 1 mL of dinitrosalicylic acid color reagent. The tubes were then incubated in boiling water for 5 min and cooled to room temperature. The solutions were diluted with 10 mL of distilled water, and absorbance was measured at 540 nm.73 Acarbose was used as the standard drug. The α-amylase inhibition percentage was calculated as follows:α-amylase inhibition (%) = [(Acontrol − Asample)/Acontrol)] × 100 The IC50 values, the concentrations required to inhibit α-amylase activity by 50%, were calculated from a non-linear regression graph of percentage inhibition (x-axis) versus concentration (y-axis) using GraphPad Prism Software (Version 5). In vitro α-glucosidase inhibition assay The inhibition of α-glucosidase activity was determined using the modified published method.74,75 One mg of α-glucosidase was dissolved in 100 mL of phosphate buffer (pH 6.8) containing 200 mg of bovine serum albumin (Merck, Germany). The reaction mixture, consisting of 10 µL of sample at varying concentrations (10–1000 µM), was premixed with 490 µL of phosphate buffer pH 6.8, and 250 µL of 5 mM p-nitrophenyl α-d-glucopyranoside (Sigma-Aldrich, Switzerland). After preincubating at 37 °C for 5 min, 250 µL of α-glucosidase (0.15 unit per mL) was added and incubated at 37 °C for 15 min. The reaction was terminated by the addition of 2000 µL of 200 mM Na2CO3. α-Glucosidase activity was determined spectrophotometrically at 400 nm using a UV-vis spectrophotometer (Shimadzu 265, Japan) by measuring the p-nitrophenol released from p-NPG. Acarbose was used as a positive control of an α-glucosidase inhibitor.76 The concentration of the extract required to inhibit 50% of α-glucosidase activity under the assay conditions was defined as the IC50 value. Statistical analysis The IC50 values, the concentrations required to inhibit α-amylase and α-glucosidase activities by 50%, were calculated from a non-linear regression graph plotted as percentage inhibition (x-axis) versus concentration (y-axis) using GraphPad Prism Software (Version 5).77 In vitro AChE enzyme inhibition assay The in vitro AChE inhibitory activity was measured using the methods described earlier.78,79 Briefly, stock solutions (1 mg mL−1) of test compounds were prepared using 1% v/v DMSO. Serial dilutions were prepared from working solutions (0.001–100 µg mL−1). The various concentrations of test compounds (10 µL) were pre-incubated with sodium phosphate buffer (0.1 M; pH 8.0; 150 µL) and AChE solution (0.28 U mL−1; 20 µL) for 15 min at 25 °C. Initiate the reaction by adding DTNB (10 mM; 10 µL) and substrate, ATChI (14 mM; 10 µL). The reaction mixture was mixed using a cyclomixer and incubated for 10 min at room temperature. DTNB is used to quantify the thiocholine produced from the hydrolysis of acetylthiocholine by AChE. The absorption intensity of the DTNB adduct is used to measure the amount of thiocholine formed, which is proportional to the AChE activity. The absorbance was measured using a microplate reader at 410 nm against a control containing 10 µL DMSO instead of the test compound.80 Donepezil (0.001–100 µg mL−1) was used as the positive control.81 In vitro BChE enzyme inhibition assay The activity of BChE was determined in the same way as AChE activity by measuring thiocholine reacted with DTNB after hydrolysis of the substrate.82 BChE solution (0.32 U mL−1; 20 µL) was used for this assay instead of AChE. The IC50 (half-maximal inhibitory concentration) was calculated by fitting a non-linear regression model to % inhibition vs. concentration, using GraphPad Prism software (version 5.3). Results are expressed as the mean ± SEM of at least three different experiments performed in triplicate. Antioxidant activity Antioxidant activities and radical scavenging properties of the synthesized compounds were clarified using various in vitro antioxidant assays, including DPPH (1,1-diphenyl-2-picrylhydrazyl) assay and ABTS (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) assay. DPPH radical scavenging assay The sample's ability to scavenge DPPH free radicals was evaluated using the standard method.83,84 The sample solutions were prepared in absolute alcohol at concentrations ranging from 0.01 mg mL−1 to 1 mg mL−1. Add 500 µL of the sample to 500 µL of DPPH solution (2 µM). After 20 min of incubation, the samples were placed in the dark at room temperature. Absorbance was measured at 517 nm; 500 µL of prepared DPPH solution and 500 µL of absolute alcohol were used as controls. A similar procedure was repeated for ascorbic acid as a standard. ABTS radical scavenging assay The standard method determined the compounds' ABTS free radical cation scavenging ability.85,86 ABTS (7 mM) was dissolved in distilled water, and 2.45 mM potassium persulfate was added to prepare ABTS free radical cations. At room temperature, the solution was kept in the dark for 12–16 h. Sample solutions were prepared in absolute alcohol ranging from 0.01 mg mL−1 to 1 mg mL−1. The samples were added to 1 mL of ABTS solution and incubated for 30 min. Absorbance was taken at 734 nm, and the procedure was repeated for ascorbic acid as a standard. Molecular docking Molecular docking studies were performed to evaluate compound binding modes against α-amylase and α-glucosidase. For this purpose, the crystal structures of human pancreatic α-amylase, α-glucosidase, AChE, and BChE with PDB IDs 1B2Y, 3WY1, 7E3H, and 5DYW, respectively, were downloaded from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB). The downloaded protein structures were checked for missing residues, which were corrected along with bond orders, while formal charges were assessed and corrected. The newly synthesized compound structures were created using the builder module, and the charges on compounds were minimized using the Merck Molecular Force Field 94×. These compounds were then docked against the prepared protein structures using the Molecular Operating Environment (MOE) software.87,88 For molecular docking, we used the Triangle Matcher method as the primary placement method and LondonDock as the placement scoring method. ‘Induced fit receptor’ algorithm was used for the refinement of the 50 generated poses, out of which the top 10 poses scored via the GBVI/WSA dG method were used for further analysis. The binding poses of the top-ranked compounds were then analyzed using Protein Ligand Interaction Profiler (PLIP), and the crucial interactions were noted. In silico drug-likeness, ADME, and toxicity predictions In silico predictions of drug-likeness and ADMET properties for acarbose, donepezil, and the most potent compounds (27, 28, and 31) were performed using the preADMET online server.89 Predicting the toxicology of small molecules is crucial for assessing their tolerability before administering them to humans or animal models. The pkCSM database offers a virtual drawing option or the option to analyze small molecules by submitting their SMILES notation. This website provides information on various toxicological effects, including AMES toxicity, hERG-I inhibition, hERG-II inhibition, human maximum tolerated dose, LD50, LOAEL, hepatotoxicity, skin toxicity, T. pyriformis toxicity, and Minnow toxicity. The website was accessed for this study, and the SMILES notation of the small molecule data from MOE was entered and analyzed using the toxicity mode.90 Consent for publication All authors have read and approved the final version of the manuscript. Author contributions Faiza Seraj: design, synthesis of target compounds, characterization of target compounds, and original manuscript writing. Mariam Maqbool: writing and editing of the manuscript. Fayaz Ali: data acquisition. Sridevi Chigurupati: performed in vitro bioactivities. Vasudevan Mani and Shatha Ghazi Felemban: performed kinetics studies of all compounds. Syeda Sumayya Tariq and Zaheer Ul Haq: performed in silico studies of the compounds and original manuscript writing. Uzma Salar: formal analysis, review, editing, and authentication of the final manuscript draft. Khalid Mohmmed Khan: overall supervision of the project, including formal analysis, review, editing, funding acquisition, and authentication of the final manuscript draft. Conflicts of interest The authors declare no financial or other conflicts of interest. No writing assistance was utilized in the production of this manuscript. Supplementary Material